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Foreword
The excellence of the UK research 
community provides an opportunity for 
future economic growth. Deriving 
significant benefits also relies on the ability 
of business to develop products and 
services and on the expectation of a 
sizeable global market. The Technology 
Strategy Board highlighted synthetic 
biology as an emerging technology 
meeting all these key criteria and offering 
particularly strong growth potential in the 
UK. A coordination group was formed 
towards the end of 2011 to chart a suitable 
way forward. 
The capacity of synthetic biology to 
develop useful applications has only 
become a practical option in recent years. 
Progress over the past decade has been 
driven by a combination of factors, not 
least an ever deepening understanding of 
biological systems and remarkable 
advances in the efficiency of DNA 
sequencing and synthesis. Specific 
applications are already emerging, but its 
long-term potential remains largely 
untapped. The sharing of understanding 
across the constituent biological and 
engineering disciplines, pooling of 
expertise and resources, anticipation of 
critical challenges and the enthusiastic 
commitment of all stakeholders will 
significantly enhance our capacity to 
benefit. Synthetic biology has the potential 
to increase prosperity and address some 
of the major challenges facing our planet 
– but much work needs to be done, and it 
has to be done responsibly. 
Engaging the synthetic biology community 
in shaping this roadmap has also 
contributed a first step towards its 
realisation, through making new 
connections and building a shared vision. 
Further initiatives, such as the recent 
formation of a special interest group, will 
continue to stimulate interest and facilitate 
cooperation. This roadmap is not a one-off 
long-term plan towards a fixed point. It 
provides a compass-bearing for the 
community, helping to align interests 
towards future growth opportunities whilst 
identifying the resources and standards 
needed to accelerate progress in the 
shorter term. 
As an independent panel we set out to 
reflect a representative view drawn from 
across the UK community. We believe we 
have achieved this, but we also recognise 
the need for ongoing and broadening 
engagement to complement what has 
been possible within the practical and time 
constraints of this exercise. Cooperation 
on an international scale will also help 
determine success. We have outlined a 
first step in the journey and see a 
leadership council helping to manage the 
ongoing process. 
I have been impressed and delighted at 
the interest, energy and enthusiasm shown 
by those who have contributed to this 
roadmap and I thank them all. In particular, 
members of the coordination group who 
have worked tirelessly for six months to 
pull together and structure all the material. 
 
 
Lionel Clarke
Chairman  
UK Synthetic Biology Roadmap 
Coordination Group 
July 2012
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Executive summary
This publication sets out a shared synthetic 
biology roadmap for the UK pulled 
together by an independent panel of 
experts at the request of the Department 
for Business Innovation and Skills (BiS).
Synthetic biology is the design and 
engineering of biologically based parts, 
novel devices and systems as well as the 
redesign of existing, natural biological 
systems. It has the potential to deliver 
important new applications and improve 
existing industrial processes – resulting in 
economic growth and job creation. 
It is a rapidly developing technology 
applicable to a wide range of biological 
systems, and has developed over the last 
decade due to the confluence of a number 
of factors. It could help to solve a number 
of major global challenges including in the 
fields of healthcare, energy and the 
environment. 
The UK was amongst the first to recognise 
and respond to the opportunities raised by 
synthetic biology. Publicly-funded academic 
studies coupled with meaningful public 
dialogue have established the foundations 
upon which the sector is now being built. 
Multidisciplinary expertise is already 
enabling the UK to make significant 
contributions to international research 
programmes, and also to assimilate and 
respond to global developments as they 
arise. 
Our goal is to build upon these foundations, 
identifying and stimulating initiatives that 
will help companies develop new products, 
processes and services of clear public 
benefit, and generate economic growth 
and create jobs. Applications could 
include biosensors to identify infections 
and diseases and trigger localised drug 
delivery; more personalised medicines, 
tailored to an individual’s specific 
requirements; improved waste treatments 
and bioremediation; and more cost-
effective routes to renewable chemicals, 
materials and fuels, leading ultimately 
towards more efficient solar energy 
conversion and storage as envisaged via 
artificial photosynthesis. A recent 
assessment by BCC research on behalf of 
Global Information Inc concluded that the 
value of the global synthetic biology 
market will grow from $1.6bn in 2011 to 
$10.8bn by 2016.
Synthetic biology is still at an early stage of 
development and relatively unproven, but 
its potential is widely considered to be very 
high. It is a platform and translational 
technology linking a broad range of 
foundational science with an extensive 
range of possible applications, some 
already progressing towards market. 
Research is moving fast, but developing 
specific processes to commercial scale 
will invariably take time and encounter new 
challenges. This roadmap takes a holistic 
view of the innovation process, to 
anticipate issues and facilitate progression 
of applications and services towards the 
ultimate goal of realising a clear vision for 
a UK synthetic biology sector. 
Five core themes for the roadmap 
emerged from this work. They were:
•	 foundational science and 
engineering: the need for sufficient 
capabilities for the UK to maintain a 
leading edge
•	 continuing responsible research 
and innovation: including the need for 
awareness, training and adherence to 
regulatory frameworks
•	 developing technology for 
commercial use
•	 applications and markets: identifying 
growth markets and developing 
applications
•	 international cooperation.
An essential first stage is the building of a 
cohesive stakeholder community including 
academics, industrialists, public and 
private organisations. Workshops held to 
date have already begun this process, 
helping to shape the vision. Energising this 
growing community around the vision, 
supported as needed through effective 
resourcing and training, will stimulate the 
development of applications of significant 
value. 
To accelerate the contribution synthetic 
biology could make towards a vibrant 
economy, it will be necessary to build 
upon the many factors that make the UK 
an excellent location to progress synthetic 
biology, whilst identifying and reducing the 
commonly encountered stumbling-blocks 
anticipated along the pathway to 
commercially viable products and 
services, particularly on behalf of smaller 
and start-up companies that may otherwise 
lack sufficient capacity or finance. 
A number of factors may enhance the 
probability of success of a given venture, 
for example, being clearer on what is 
possible, understanding earlier in the 
process what is needed, gaining access to 
a wider range of resources including 
relevant training and advice, having more 
effective mechanisms to share ideas and 
Our vision is of a UK synthetic 
biology sector that is: 
•	 economically	vibrant,	diverse	and	
sustainable: where businesses have 
successfully developed and 
introduced new products, processes 
and services – leading to significant 
revenues and employment
•	 cutting	edge:	leading	scientific	
advances and with a resilient 
platform of underpinning 
technologies – delivering clear 
advantages in application 
development 
•	 of	clear	public	benefit:	an	exemplar	
of responsible innovation, 
incorporating the views of a range of 
stakeholders and addressing global 
societal and environmental 
challenges within an effective, 
appropriate and responsive 
regulatory framework.
A synthetic biology roadmap for the UK
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best practice across the community and 
having access to a wider network of 
potential partners and sources of public 
and private funding. 
Initiatives have already been taken in the 
UK to establish a multidisciplinary 
community, supported via dedicated 
educational programmes and facilities, 
including the establishment of a Centre for 
Synthetic Biology and Innovation. But 
more must be done to nurture and 
advance these foundations if the UK is to 
retain its relatively strong and innovative 
position on the global stage. 
Our recommendations, summarised right, 
therefore seek to strengthen, stimulate and 
better integrate knowledge-generation 
within the UK academic research base 
whilst simultaneously developing routes to 
commercialisation. Demonstrating a 
consistent, long-term commitment, based 
around a clearly stated and broadly 
supported vision will be very important in 
ensuring the stability needed to attract 
ongoing investments and in assisting 
alignment of core research interests. 
Synthetic biology in the UK operates within 
the existing regulatory framework and 
routinely takes account of social and 
ethical issues. Nevertheless, we highlight 
the need to continue practising 
responsible research and innovation at all 
stages. To ensure that practitioners 
continue to be fully aware of potential 
issues, and that regulatory frameworks 
remain current with leading-edge 
developments, it will be important to 
maintain effective ‘open-door’ 
mechanisms for dialogue. These, in turn, 
will inform, and be informed by, ongoing 
formal national policy and international 
regulatory review mechanisms. 
Considering these various needs, we 
recommend a package of measures that 
should support and develop the UK-wide 
research and industrial communities by 
enhancing the availability of essential 
resources and information. 
Specifically, we recommend the creation 
of a network of multidisciplinary centres, 
including a dedicated innovation and 
knowledge centre (IKC), to both strengthen 
and expand our foundational and applied 
research base and facilitate business 
exploitation. These should all be based 
within existing higher-education 
institutions. Investment plans for early-
stage and larger demonstrator projects 
and for feasibility studies should also be 
made in the near future to facilitate 
industrial applications of the technology. 
A variety of mechanisms should be 
introduced via the Technology Strategy 
Board, research councils and others as 
appropriate, to extend the UK-wide 
synthetic biology community. Such 
mechanisms may include the formation of 
an overarching network for synthetic 
biology – through the formation of a 
special interest group (SIG), holding an 
annual forum and funding competitions to 
support the development of novel 
applications. Forming a coherent, 
energised synthetic biology community 
should stimulate an innovative ‘can do’ 
culture and create an environment 
conducive to attracting inward investment. 
It should also facilitate increased levels of 
interaction between the research community 
and other stakeholders including the public.
Realising the vision for synthetic biology 
should allow the UK to make a positive 
contribution to the global response to 
challenges in areas such as health and the 
environment. In this way, the UK may 
reasonably seek to build on its current 
strengths and assume a leading international 
role in synthetic biology, helping to set 
standards and shape future regulations. 
This may be achieved through a variety of 
mechanisms, such as participating in 
trans-national grant funding, hosting 
international conferences and continuing 
to foster coordinated efforts in synthetic 
biology through research partnerships.
Finally, a leadership council should be set 
up to own and oversee continual 
development and delivery of the vision. 
This will provide a focal structure for 
assessing progress and updating 
recommendations and priorities within the 
roadmap.
Recommendations
1. Invest in a network of 
multidisciplinary centres to establish 
an outstanding UK synthetic biology 
resource
2. Build a skilled, energised and 
well-funded UK-wide synthetic 
biology community
3. Invest to accelerate technology 
responsibly to market
4. Assume a leading international role
5. Establish a leadership council 
The UK is an excellent place to 
progress synthetic biology because 
it has: 
•	 a	healthy	ecosystem	for	new	and	
established businesses (UK ranked* 
in the top 5% of countries for ‘ease  
of doing business’)
•	 a	strong	academic	base	in	synthetic	
biology, linked to a very strong 
innovative culture and heritage 
across the life sciences, engineering 
and physical sciences
•	 a	strong	and	internationally	networked	
industrial base in application areas 
for synthetic biology
•	 agile	and	responsive	funding	agencies
•	 proportionate	and	robust	regulatory	
frameworks that are internationally 
recognised and well regarded
•	 strong	UK	Government	support.	
*World Bank Survey 2011
A synthetic biology roadmap for the UK
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Introduction
Industry, academia, government 
organisations, funders and others 
have joined forces to produce a 
roadmap for the formation of a 
world-leading synthetic biology sector 
in the UK. Synthetic biology could 
help to tackle major global challenges 
in areas such as healthcare, energy 
and the environment and is already 
starting to deliver high-quality jobs. 
Synthetic biology’s contribution to  
the knowledge-based bio-economy 
(and the wider economy) is predicted 
to grow increasingly in the short, 
medium and long term. 
The UK was amongst the first to recognise 
and respond to the opportunities raised by 
synthetic biology. Publicly-funded 
academic studies, coupled with 
meaningful public dialogue, have 
established the foundations upon which 
the sector is now being built. 
Multidisciplinary expertise is already 
enabling the UK to make significant 
contributions to international research 
programmes and to assimilate and 
respond to global developments. Our goal 
is to build upon these foundations, 
stimulate a vibrant innovation culture within 
the UK and lead towards the delivery of 
products and services of clear economic 
and public benefit.
This publication sets out a shared 
roadmap for the UK drawn together by an 
independent panel of experts at the 
request of the Department for Business 
Innovation and Skills (BIS). The vision and 
recommendations for the UK grew out of a 
series of workshops attended by more 
than 70 people representing a broad 
range of stakeholders from industry, public 
bodies, academia and other organisations. 
It also draws upon the large and rapidly 
growing body of world literature and the 
numerous conferences, symposia and 
discussion forums that have recently 
focused on synthetic biology. Although 
specifically a roadmap for the UK, working 
with international stakeholders remains an 
essential part of implementing the 
roadmap (as reflected in our 
recommendations). We reviewed a 
number of thematic areas in reaching a set 
of recommendations, which, if advanced 
effectively, will establish and grow a 
successful synthetic biology sector.
The definition of synthetic biology we used 
is adapted from the 2009 Royal Academy 
of Engineering study.
Synthetic biology is the design and 
engineering of biologically based 
parts, novel devices and systems as 
well as the redesign of existing, 
natural biological systems. It has the 
potential to deliver important new 
applications and improve existing 
industrial processes – resulting in 
economic growth and job creation. 
Our vision is of a UK synthetic biology 
sector that is: 
•	 economically vibrant, diverse and 
sustainable: businesses have 
successfully developed and introduced 
new products, processes and services 
– leading to significant revenues and 
employment
•	 cutting edge: leading scientific 
advances and with a resilient platform 
of underpinning technologies – 
delivering clear advantages in 
application development 
•	 of clear economic and public 
benefit: an exemplar of responsible 
innovation, incorporating the views of a 
range of stakeholders and addressing 
global societal and environmental 
challenges within an effective, 
appropriate and responsive regulatory 
framework. 
A synthetic biology roadmap for the UK
UK SYNTHETIC BIOLOGY ROADMAP COORDINATION GROUP | 07
Global trends and the role of synthetic biology
The world is becoming increasingly 
interconnected and the ability to 
generate, share and interpret data on 
a massive scale is accelerating our 
ability to understand highly complex 
systems. The emergence of synthetic 
biology as a distinct discipline through 
the first decade of this century is a 
clear example of this trend.
Potential applications of synthetic biology 
arise wherever biological systems play a 
role, or could play a role in future. Fields of 
increasing interest at individual and 
societal levels include well-being (such as 
prediction and prevention of diseases, 
personalised healthcare, improved 
lifestyle, employment), security (including 
food, water and energy security) and 
sustainability (meeting the challenges of 
managing natural resources, reducing 
dependence on non-renewable resources 
and finding ways to mitigate climate 
change). Objectives for envisaged 
synthetic biology applications in these 
fields include reduction in costs, extended 
or novel functionality and greater 
selectivity. However, as an emerging 
platform technology, the potential for 
synthetic biology to develop valuable 
applications in areas as yet unconsidered 
remains a significant future possibility. 
Addressing these fields of interest and 
other global challenges will continue to 
generate a wealth of potential applications. 
There are no unique solutions to these 
global challenges – the issues are 
complex and changing, and effective 
responses will require a combination of 
scientific, technological and political 
options. Nevertheless, as strategies for 
maintaining or improving quality of life and 
the environment play out within an 
expanding global population, we expect 
the ongoing development of biological 
systems to play an important role in the 
global quest for solutions and to provide 
an expanding channel for relevant 
applications of synthetic biology. 
Synthetic biology is still at an early stage of 
development and relatively unproven, but 
its potential is widely considered to be 
great (and from some perspectives 
revolutionary). It is a platform technology 
with an extensive range of possible 
applications, a few of which are already 
progressing towards market, with many 
others under consideration. 
It can take many years to develop 
technologically robust, safe and 
commercially viable solutions, yet the 
need for effective solutions to social and 
environmental challenges is increasingly 
urgent. This roadmap anticipates some of 
the mechanisms and resources we need 
to consider now in order to better respond 
to emerging opportunities and challenges. 
It is too early to assess the full extent to 
which synthetic biology will address these 
challenges over the longer term. 
Nevertheless, the relevant global markets 
are substantial and growing. For example, 
biopharmaceuticals (pharmaceuticals 
Well - being Security Sustainability
• Predict/ prevent diseases
• Employment
• Food
• Water
• Energy
• Manage natural resources
• Reduced dependence on
non-renewable sources
• Climate change mitigation
• Personalised healthcare 
Population
Quality of Life Environment
Figure 1: No unique solution can fully address the material needs of a growing global population, but technology developments in  
the biological sciences can play a role in responding responsibly to the underlying needs for security, sustainability and well-being.  
This in turn provides a number of channels where synthetic biology may make potentially significant long-term contributions. 
Global needs with links to synthetic biology
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derived using biotechnology) are now 
estimated to be around 20% of all 
medicines, effectively double what they 
were a decade ago. As synthetic biology 
starts to play an increasing role in 
medicines and healthcare, it is becoming 
possible to assess the global scale of the 
future market, at least in the near future. 
Other established markets provide further 
benchmarks for potential application – for 
example, it is estimated that 2010 revenues 
from industrial biotechnology in the US 
alone were approximately $100bn1. It is 
also estimated that P5bn may be added to 
the European bio-economy by 2025 from 
ongoing research activities2.  
Such assessments depend greatly on the 
assumptions used, not least the definition 
of synthetic biology itself and what is, or is 
not, appropriate to include in the definition 
of the market sector. One of the most 
comprehensive assessments available is 
that by BCC Research on behalf of Global 
Information Inc. By surveying data 
available from leading companies, life 
science research institutions, thought 
leaders and numerous secondary 
sources, they compile an assessment of 
global applications and forecast sales 
revenues over the coming five-year period. 
They conclude that the value of the global 
synthetic biology market will grow at a 
substantial rate, from $1.6bn in 2011 to 
$10.8bn by 2016. In the longer term, 
synthetic biology also has the potential to 
deliver into new, as yet undiscovered, 
markets in response to emerging future 
needs. Regardless of the accuracy of 
these estimates, there is strong evidence 
from this and the indicators above that the 
prospects for future growth are substantial.
1  Biodesic 2011 Bioeconomy Update: www.biodesic.com/
library/Biodesic_2011_Bioeconomy_update.pdf
2  Innovating for Sustainable Growth: A Bioeconomy for 
Europe. Communication from the commission to the 
European Parliament, the Council, the European 
Economic and Social Committee and the Committee of 
the Regions, Brussels 13.2.2012 COM(2012) 60 final.
A synthetic biology roadmap for the UK
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The UK has a long tradition of world-
leading intellectual activity. We have a 
reputation for ‘punching above our 
weight’, possessing world-leading 
groups that over many years have 
consistently delivered significant 
breakthroughs in a wide range of 
disciplines, including bioscience, 
engineering and ICT. 
Our innovative culture is one of independent 
and progressive research, which has at its 
heart ideas and products that challenge the 
status quo. The UK is a healthy ecosystem 
for new and established businesses.  
We have moderate levels of corporation 
tax with ‘patent box’ arrangements  
for exploiting intellectual property, and 
generous company tax breaks to 
encourage research and development.  
We need to reduce the risks encountered 
along the pathway to commercially viable 
synthetic biology products. This will be 
achieved through a variety of tailored 
mechanisms, including a highly skilled, 
flexible workforce trained by our excellent 
universities and colleges. Furthermore, UK 
research and development is protected 
and enabled by ethical and regulatory 
frameworks that are recognised around 
the world as robust and proportionate.
Substantial government investment 
underpins UK knowledge-based 
innovation. Total public investment in the 
research base, through the research 
councils and the Higher Education 
Funding Council for England (HEFCE),  
is around £6bn a year. The Technology 
Strategy Board, the UK’s innovation agency, 
invests a further £350m a year helping 
4,000 companies across all technology 
domains and business sectors develop 
new products, processes and services. 
Recent UK government announcements 
committed £75m for the ELIXIR research 
infrastructure to handle the rapidly growing 
volume of biological data from high-
throughput experiments such as DNA 
sequencing and £145m to improve 
Britain’s e-infrastructure to drive growth 
and innovation. An investment of £380m 
has been made by EPSRC in cutting-edge 
manufacturing research with over 340 
current research grants and 1100 
collaborating companies. This includes a 
£45m recent investment in nine new 
Centres for Innovative Manufacturing,  
all working closely with businesses to 
UK strengths 
TSB, BBSRC 
and EPSRC  
launch 
industrial 
feasibility call 
£6.5m  
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Figure 2: Funding for synthetic biology has been consistently applied by UK research councils since 2007, totalling more than 
£62m ($95m) to date. 
Acronyms: NSF (United States, National Science Foundation) ICSTM (Imperial College of Science, Technology and Medicine), 
Dstl (Defence Science and Technology Laboratory), ESF (European Science Foundation), MRes (Masters in Research) and 
ERA-NET (European Research Area Networks)
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stimulate growth in a number of areas.  
An investment of £250m has been made 
by the BBSRC, including 26 strategic 
science programmes and 14 key national 
research capabilities, to meet challenges 
such as sustainably feeding the growing 
world population and finding alternatives 
to dwindling fossil fuels. The Technology 
Strategy Board is to invest £200m in seven 
Catapults – a network of technology and 
innovation centres. Other recently 
announced investments in supporting 
infrastructure include £16m in robotics 
(£12m from the Government to 19 
universities, with a further £4m from 
industry) providing access to specialist 
laboratories, equipment and expertise 
across a number of sectors.
A recent study has identified that synthetic 
biology research is now being funded in 
40 countries via more than 500 funding 
organisations, and carried out by a 
research community comprising an 
estimated 3000 researchers. The UK is 
second only to the US in publication 
output3. Publication output from Europe as a 
whole is comparable to the US. This places 
the UK in a pivotal position to influence 
and benefit from this internationally 
expanding field. 
In terms of synthetic biology, there is a 
very significant presence in those sectors 
that are expected to commercialise the 
technology, especially in chemicals, 
biosciences and pharmaceuticals, 
advanced materials and energy. For 
companies in these sectors, indeed in all 
sectors, the UK is recognised as an 
excellent place to do business. It was 
ranked in the top 5% (7th out of 183 
countries globally) for ‘ease of doing 
business’ according to a World Bank 2011 
survey4. According to the Chemical 
Industries Association, it remained, in 
2009, the number one inward investment 
destination in Europe, with almost one fifth 
of the total accumulated stock of foreign 
direct investment. In 2007/08, the UK 
attracted 1,573 foreign direct investment 
projects from 48 countries, a record-
breaking performance. The UK accounts 
for 57% of the whole European private 
equity and venture capital market5. 
The UK chemical industry comprises a 
major sector in the UK, with over 3,000 
companies in 2009 (generating an annual 
turnover of around £55bn). Growth in this 
sector in recent years has been roughly 
5% a year, with the UK having in excess of 
8% of the world market. 
The UK has one of the most dynamic and 
innovative healthcare industries in the 
world. It has developed over 20% of the 
world’s top 100 selling medicines (second 
only to the US, and more than the rest of 
Europe combined). Every one of the top 10 
pharmaceutical companies in the world 
has a presence here. GlaxoSmithKline6 
has recently committed to invest more 
than £500m across its manufacturing sites 
in the UK to increase production of key 
active ingredients for its pharmaceutical 
products and vaccines. Together with 
AstraZeneca, these two companies alone 
report a combined turnover of £42bn 
(approximately 9% of the global market). 
In 2007, the value of UK pharmaceutical 
exports was £14.6bn, bringing in a trade 
surplus of £4.3bn. The pharmaceutical 
sector in the UK consists of around 600 
companies and employs some 67,000 
people. According to the Department for 
Business Innovation and Skills (BIS) 2009 
R&D Scoreboard, pharmaceutical and 
biotechnology R&D expenditure in the UK 
UK biotechnology built on strong heritage
The UK has a strong heritage in biotechnology which underpins not only world-class 
academic research, but also a vibrant biotechnology industry. 
The discovery by James Watson and Francis Crick of the structure of DNA in 1953 and 
seminal follow-up work by Crick in 1961 that cracked the DNA-to-protein code, laid the 
foundations on which all synthetic biology designs now rely. UK expertise led to the 
discovery of reverse transcriptase (now an indispensible part of molecular biology) and 
the development by Frederick Sanger in 1977 of a vastly improved sequencing method. 
This led to huge scientific advances including the Human Genome Project. 
In the 1990s, Professor Shankar Balasubramanian and Professor David Klenerman of 
the University of Cambridge invented Solexa sequencing: an ultrafast method for 
sequencing DNA that improved cost and speed by 1,000 to 10,000 fold on previous 
technologies. Solexa was sold to Illumina for $600m in 2007 and is the global market 
leader in next generation sequencing. This expertise has continued to the present day. 
Oxford Nanopore Technology (ONT) has developed a new sequencing technology 
based on fundamental research from the University of Oxford which works by running a 
strand of DNA through a tiny hole called a nanopore. Developments like these are 
leading to a point where DNA can be sequenced in real time, opening up exciting new 
possibilities for medicine and biotechnology.
3  Synthetic Biology: Mapping the Scientific Landscape; 
Oldham, P; Hall, S; Burton; G. (2012), PLoS ONE 7,4
4  World Bank. Ease of doing business survey 2011.  
www.doingbusiness.org/rankings
5 UKTI. Chemicals – the UK advantage. 2009.
6 www.gsk.com/media/pressreleases/2012/2012-
pressrelease-994808.htm
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in 2008 was £9.6bn. The medical 
technology sector in the UK consists of 
around 2,800 companies, employing 
52,000 people and generating around 
£10.6bn of turnover a year. 
The UK clinical and health sciences 
research base is second only to the US in 
terms of global impact. It has provided a 
creative crucible for the discovery of new 
medicines over many decades. The UK 
has several universities that regularly 
appear in the top ten of university ranking, 
and a strong legacy of Nobel laureates in 
the areas of medicine, physiology or 
chemistry. Over the last decade, UK 
university bioscience departments have 
generated over 200 spin-out companies7,8.
The UK also has major strengths in advanced 
engineering, manufacturing and design. 
The potential for synthetic biology to 
produce high-tensile-strength and other 
advanced materials may well find value in 
application fields such as aeronautical 
engineering. 
Bioenergy accounts for 3% of total primary 
energy consumption in the UK, with the 
majority (65%) being used in power 
generation and contributing towards the 
delivery of the UK renewables target9.  
Both Royal Dutch Shell and BP have 
significant global biofuel interests, and, 
together with their partnerships and joint 
ventures, promote some of the world’s 
largest research, development and 
commercial renewable fuel programmes.  
In 2010, the energy supply industry in the 
UK contributed approximately 4% of GDP 
(£60bn), 10% of total investment, 52% of 
industrial investment, and directly 
employed approximately 173,000 people10. 
The UK energy research community also 
produces recognised high-quality research11 
across a variety of energy technologies. 
The Biotechnology and Biological 
Sciences Research Council’s (BBSRC) 
Sustainable Bioenergy Centre is a £27m 
investment in bioenergy research. The 
centre brings together six world-class 
research groups and 15 leading industrial 
associates. 
7  Royal Society (2010). The scientific century. Securing  
our future prosperity. http://royalsociety.org/policy/
publications/2010/scientific-century/ 
8  Office for Life Science and UK Trade and Investment 
(2010). Life science. The UK: collaboration for success. 
http://webarchive.nationalarchives.gov.
uk/20110120011807/bis.ecgroup.net/publications/
uktradeinvestment/uklifescience/10579.aspx
9 UK Bioenergy Strategy, 2012
10 UK Energy In Brief 2011, DECC.
11  Report of the International Panel for the 2010 RCUK 
Review of Energy
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Synthetic biology is the design and 
engineering of biologically based 
parts, novel devices and systems as 
well as the re-design of existing, 
natural biological systems. The step 
change in the synthetic biology 
approach is to engineer biological 
systems to perform new functions in a 
modular, reliable and predictable way, 
allowing modules to be reused in 
different contexts. It has the potential 
to deliver important new applications 
and improve existing industrial 
processes across many sectors 
including healthcare, energy, 
pharmaceuticals, materials, and 
remediation – resulting in economic 
growth and job creation. 
Synthetic biology has developed over the 
last decade. The field arose from the 
confluence of a number of factors. First, 
the revolution in molecular biology that has 
occurred over the last 60 years and in 
which the UK has played a leading role.  
A significant development was DNA 
sequencing, which during the 1990s and 
early 2000s yielded the genome 
sequences of a handful of important 
species. From the standpoint of synthetic 
biology, efficiency gains from next-
generation sequencing have led to 
industrial-scale enterprises with potential 
to open up nature’s vast reservoir of 
biological information and, with it, 
identification of novel biological parts. 
Coupled to this, the development of 
reliable, chemically based, DNA synthesis 
is allowing the alteration and construction 
of DNA sequences, their use in existing 
biological chassis, and the possibility of 
building whole genomes from scratch. 
Second, the development of our 
understanding of biological systems and 
how to manipulate them is advancing at 
pace through systems biology, 
bimolecular sciences and related fields. 
This all means that we can now attempt 
the design and engineering of biological 
systems with increased confidence and 
success.
Importantly, synthetic biology is a 
translational field that takes foundational 
research from a range of fields (for 
example, biochemistry, systems 
engineering, molecular biology, plant 
sciences, chemical engineering, 
informatics, microbiology) and integrates 
and builds upon these findings through 
the application of engineering design 
principles. This is possible because 
biological systems are inherently modular 
and biological function – usually expressed 
through proteins and RNA – is primarily 
encoded in DNA. In addition, biological 
control and regulatory elements can be 
defined (for example, logic gates, feedback 
systems, amplifiers and oscillators). An 
objective of the field is therefore to utilise 
the diversity of biological parts (genomes 
and metagenomics, synthetic parts/
components) to build new biological 
devices and systems with defined function. 
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Synthetic biology 
‘Clicking’ DNA and RNA
Professors Tom Brown (University of Southampton) and Andrew Turberfield (University 
of Oxford) are leading a collaboration developing a technique for producing DNA and 
RNA structures more efficiently and on a larger scale than is possible using current 
enzyme-based technologies. They have ‘clicked’ DNA and RNA segments together 
using a chemical method which could allow long strands of DNA to be produced in 
large amounts for industrial-scale applications. The ability to ‘click’ DNA together opens 
up the possibility of producing new DNA structures decorated with a variety of useful 
chemical modifications for industrial uses in the UK bioeconomy, including in clinical 
applications, for example to ‘switch-off’ disease genes.
Cost per base of DNA sequencing and synthesis
Rob Carlson, June 2011, www.synthesis.cc
Figure 3: The cost of DNA sequencing has plummeted over the past two decades whilst more 
modest reductions have been achieved to date in synthesis
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The engineering concepts of 
modularisation, characterisation and 
standardisation are central to the field. 
Here, modularisation is defined as the 
process of breaking down a biological 
system into a series of well-defined, 
standard parts or components (for 
example, a gene, protein, a pathway, a 
microbe in a culture). Characterisation is 
the process of defining the behaviour and 
function of these parts in particular 
contexts in order to understand how they 
can be used in human-defined design. 
Standardisation means that the design 
process is based on well-defined standard 
modules that can be interfaced to produce 
a device or system. It is accepted that 
interfacing biological parts will be 
challenging, and issues relating to context 
dependency, predictability and robustness 
will need to be tackled. The standardisation 
of components and processes generated 
significant advances in mature engineering 
disciplines, and a major challenge for 
synthetic biology is to put biological 
systems’ engineering on the same footing. 
Synthetic biology comprises a translational 
process achieved through the deployment 
of platform technologies, within a 
framework of robust engineering principles 
and practices. These platforms harness 
informatics (for example, databases, 
Bio-CAD software), analytical technologies 
(DNA synthesis and assembly, 
sequencing, metabolic and proteomic 
profiling) and biological technologies (for 
example, host cell systems) in the process 
of systematic design. Another key 
component of the translational process is 
interplay between experiment and theory, 
and the application of a synthetic biology 
design cycle. The cycle comprises the 
following steps: specification, design, 
modelling, implementation, testing and 
validation. These approaches are central 
to enabling the creation of industrial 
products when integrated with new 
scale-up methodologies, and 
industrialisation is one important end point 
of synthetic biology. Another important 
end point is the contribution that synthetic 
biology will make to the fundamental 
understanding of bioscience, which, 
combined with rapid and significant 
developments across the related 
underpinning biosciences themselves, will 
stimulate further generations of industrial 
products made using this approach. 
Synthetic biology is now poised to have an 
important industrial future in a range of 
fields. Figure 4 illustrates how the 
underpinning academic disciplines 
contribute to the methodology to create 
devices, networks and systems as part of 
the synthetic biology translation process. 
This leads to industrial processes which, in 
turn, leads to products. 
Industrialisation and market sectors
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 Biochemistry Protein Directed  Metabolic  Genomics  Systems  Systems
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Figure 4: Synthetic biology is both a platform 
technology (building a systematic basis for 
design – combining biological, engineering 
and computational capabilities) and a 
translational technology (providing the link 
between a wide range of underpinning 
disciplines – ranging from biochemistry to 
systems theory – and practical applications 
in a wide range of different market sectors)
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The primary purpose of this 
technology roadmap is to establish a 
vision for synthetic biology in the UK, 
and to identify the processes that 
must be applied to realise it. It 
provides a framework within which to 
consider future options and 
coordinate actions. Because synthetic 
biology is an emerging and fast-
developing sector, the purpose of the 
roadmap is not to provide a detailed 
project plan but, more importantly, to 
determine those core elements that 
need to be put in place as a secure 
platform upon which innovative 
developments may build in future.  
The process of generating the 
roadmap is itself an integral part of 
opening up stakeholder discussion, 
seeking consensus and starting the 
process of building an informed, 
energised and effectively supported 
UK-wide community. 
This roadmap has been produced during 
2012 by an independent panel of experts 
at the request of the UK Department for 
Business Innovation and Skills. It 
incorporates material generated during 
two UK roadmap workshops attended by 
70 participants representing a broad range 
of stakeholders from industry, public 
bodies, academia and other organisations. 
The workshops followed a process 
established through extensive experience 
by the Institute for Manufacturing (IfM) in 
Cambridge, ensuring substantial 
engagement of all participants and 
generating a wealth of valuable material 
and insights. The roadmap has also been 
heavily informed by the large and rapidly 
growing body of world literature and the 
outputs of the numerous conferences, 
symposia and discussion forums that have 
focused on synthetic biology in recent years. 
Fundamental to the roadmap study, as 
applied in the workshops, has been the 
need to consider the activity as a whole, 
taking an integrated overview of all key 
influences upon and stages within the 
process, whilst informing the discussion 
with essential details and knowledge from 
experts representing a broad cross-
section of stakeholders. Our intention 
throughout has been to identify early the 
steps that must be taken along the 
journey, to avoid delay in anticipating and 
responding to the opportunities and 
challenges that lie ahead, and to 
recognise that there are many other 
stakeholders whom we would encourage 
to engage in further shaping the way 
forward as the community develops. 
The workshops considered the roadmap 
landscape as a whole, across a range of 
timeframes, stretching out towards a post 
2030 vision. This was populated in detail 
from both a ‘top-down’ perspective, 
considering trends and drivers, and a 
‘bottom-up’ perspective, considering 
enablers, capabilities and technology, 
leading to consideration of value-creation 
opportunities and value-chain 
perspectives. Key outcomes are 
summarised in the A3 fold-out ‘UK 
Synthetic Biology in the UK: Roadmap 
Landscape’ graphic at the back of this 
publication. The individual elements 
captured in this diagram are not intended 
to represent a comprehensive set of 
activities with precise timings, but rather to 
represent, through their entirety, an 
illustration of the broad landscape, the 
options available and the timescale that 
must be considered. It is clear that 
synthetic biology should not be 
approached in a sequential, piecemeal 
fashion, but as an integrated whole, 
addressing issues across the entire 
landscape in the short term, whilst 
maintaining a long-term perspective. 
By focusing on value-chain perspectives, 
and considering the various processes 
that apply when nurturing ideas to market, 
for example, from academia through SME/
start-up companies to large industry, we 
were better able to identify key needs that 
should be addressed in nurturing the 
emergence of a vibrant future industry. 
Important considerations identified in the 
workshops included the need to be clear 
what should be the main areas of focus, 
recognising the need for genuine market 
pull for products and for selecting key 
categories in which the UK can excel, and 
how to accelerate progress – reducing 
development time to market – 
acknowledging the essential role of public 
funding. 
A wide spectrum of applications can be 
envisaged, each specific application 
having its own particular trajectory in 
scope and time, from concept through to 
commercialisation. Although each 
individual application will face its own very 
specific development programme issues, 
a number of generic success factors could 
be identified from the many worked 
examples we considered. By addressing 
those generic factors, we can create a 
more broadly supportive operating 
environment and facilitate progress across 
the entire range of potential applications. 
A fundamental challenge is to reduce the 
development time and cost to market. 
Effective links between academia and 
industry are important throughout, 
although the balance of engagement will 
shift towards industry as the concept steps 
towards market deployment. Taking an 
integrated approach to the whole is critical 
to rapid development, but, in practice, 
development and scaling-up of a concept 
tends to be stepwise as new challenges 
emerge. This approach is captured 
schematically in figure 5, opposite. There 
are many different ways of clustering and 
defining the various stages, but this is not 
critical to the scheme. For illustration, we 
consider progression through four stages, 
A technology roadmap
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namely from the initial capability 
(foundational and enabling science and 
engineering) to innovation of the concept 
(technology providing capability) to initial 
value creation (proof of the application) 
and finally to value capture (scale-up and 
market growth).
To facilitate progression within each stage, 
and from one stage to the next, a number 
of things need to be in place. These can 
be broadly split between generics that 
provide a supportive environment – 
regulatory frameworks, education and 
skills, stakeholder participation, 
multidisciplinary funding – and those that 
provide a more specifically technical 
underpinning such as availability of 
dedicated resources, access to an expert 
community and links between academia, 
industry and government. Moreover, the 
critical role of demonstration as a rate-
limiting step in progressing through every 
stage from the scientifically possible to the 
technologically real has been clearly 
identified by the Technology Strategy 
Board12. The benefits of international 
cooperation apply equally to generic and 
technological issues.
Starting from these broad insights and the 
wealth of information gathered from the 
workshops and other mechanisms as 
outlined above, we explore in more detail 
the issues and requirements arising, 
clustered broadly under five main themes. 
12  Emerging Technologies and Industries – Strategy 
2010-2013, TSB February 2010. www.innovateuk.org 
see under publications/strategy
TECHNOLOGY:
Capability
APPLICATIONS:
Value creation
MARKET GROWTH:
Value capture
Multi-disciplinary funding – sufficient and sustained to build technological capacity and maintain leading edge
Regulatory Frameworks and Standards – always effective and streamlined - adapting as needed
Education and Skills – from cross-disciplinary awareness and interest through to accredited professionals
Transparency and Stakeholder Participation – meeting significant needs, delivering benefits, addressing issues
Multidisciplinary funding; r gulato y frameworks; 
education and skill ; transp re cy and stakeholder participation
SCIENCE and 
ENGINEERING:
Foundational and 
enabling 
Time
Market
value
Figure 5: Facilitating progression of an idea through to market in terms of speed and likelihood of 
success can be achieved by generating a more receptive and supportive operating environment 
and providing access to critical resources relevant to each stage of development. The precise 
requirements for any specific idea will be unique, but addressing these generic challenges will 
enhance the overall synthetic biology translation process 
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A number of recurring ideas, 
observations and issues emerged that 
we consider directly relevant to the 
generation of a UK roadmap for 
synthetic biology. We have gathered 
these into five core themes.
The first theme ‘foundational science and 
engineering’ relates to the underpinning 
technological potential of synthetic biology 
and the need to establish sufficient and 
accessible capabilities within the UK to 
maintain a leading edge.
The second theme ‘continuing responsible 
research and innovation’ is the recognition 
that the ground-breaking opportunities 
and benefits arising from synthetic biology 
also come with the potential for 
unintended consequences, which can be 
avoided through awareness, training and 
adherence to prevailing regulatory 
frameworks. 
The third theme ‘developing technology for 
commercial use’ recognises that it can be 
very difficult to take an idea from the 
laboratory environment through to a 
fully-scaled industrial product or service. 
Steps need to be taken to help overcome 
the more challenging hurdles so that 
important opportunities do not fail for 
readily avoidable reasons.
The fourth theme ‘applications and 
markets’ is the identification of future 
growth markets and the development of 
suitable applications that would gain from 
more effective interactions between the 
academic and industrial communities.
The fifth theme we consider here is 
‘international cooperation’. Realising the 
vision for synthetic biology should allow 
the UK to play a positive role in the 
international response to global challenges, 
including helping to set standards and 
suitable operating frameworks. 
It will be clear that these core themes are 
mutually linked and must be addressed 
collectively to achieve a successful outcome. 
Themes
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Synthetic biology is an emerging area 
arising out of the confluence of 
several core disciplines. It integrates 
knowledge, principally from biology, 
engineering and chemistry, to create 
new products and processes. A 
by-product of this process is 
increased understanding of biological 
systems. The UK already possesses 
world-class expertise within these 
core disciplines – this provides the 
strong foundation upon which 
synthetic biology is being built. A 
strong message that emerged from the 
road mapping workshops was that 
innovation in academia and 
multidisciplinary confluence are key 
drivers of the field. 
To date, UK research funding for synthetic 
biology has come principally from the 
Biotechnology and Biological Sciences 
Research Council (BBSRC) and the 
Engineering and Physical Sciences 
Research Council (EPSRC). The funding 
has supported community networks to 
initiate research partnerships, a specialist 
centre, strategic funding for technologies 
and applications, and high-risk/high-reward 
studies to explore potential in new areas. 
International collaboration has resulted in 
funding to UK universities from a range of 
sources including the EU, the Gates 
Foundation and joint programmes with the 
US National Science Foundation. These 
grants are important because they establish 
collaboration with other leading international 
groups and show the quality of the UK 
academic base in synthetic biology.
Multidisciplinary centres  
and funding 
There is a need to capitalise on these 
investments and the research undertaken. 
The UK has one funded centre in synthetic 
biology at Imperial College and several 
other large-scale investments also 
developing platform technologies 
(Southampton and Oxford; Warwick) and 
applications including second generation 
biofuels (Nottingham). A recent 
development is the formation of a 
consortium for synthetic biology 
comprising Imperial College, Cambridge, 
Edinburgh and Newcastle universities and 
King’s College London. This aims to 
further establish a significant infrastructure 
and resource for synthetic biology within 
the UK and in support of international 
collaborations13. In addition to these 
specific examples, there are many other 
significant groups actively engaged in 
directly related research, funded by 
various research councils, industry and 
other funding bodies (the BBSRC and 
EPSRC alone support more than 30 
different higher education institutions in 
related fields). For the UK to fully leverage 
its capabilities as a basis for industrial 
growth, it will be important to coordinate 
support for synthetic biology research 
centres and corresponding research 
agendas that can facilitate the integration 
of the UK’s research and training capability 
in the field, ensure good access to 
leading-edge equipment and generate 
more opportunities to interface with industry. 
It has already been proposed that an 
innovation and knowledge centre (IKC) for 
synthetic biology should be established as 
an important mechanism towards driving 
technology towards commercialisation. 
This is described in more detail in theme 3. 
It is, however, essential to establish how 
the hub will integrate with the research 
centres – the concepts of multidisciplinary 
research centres and a commercialisation 
centre must be developed as an integrated 
whole. Concentration of research funding 
into academic centres of excellence is a 
feature of synthetic biology investment in 
the US, China and EU. The UK centres are 
necessary to build on our strong 
foundations and to create bioengineered 
solutions to underpin the UK bioeconomy. 
Recognition of the social sciences’ and 
humanities’ research effort in synthetic 
biology, together with potential 
applications in the biomedical arena, may 
lead to an increase in strategically 
coordinated research councils’ funding.
In 2007, the UK research councils 
established seven research networks in 
synthetic biology to bring together different 
disciplines, to develop a common language 
and to develop potential research projects. 
The networks integrated a strong social 
and ethical dimension into their activities 
and involved ten universities with 
considerable researcher outreach.  
The grants for the existing seven  
networks have recently come to an end.  
The roadmap workshops have identified  
the need for continued multidisciplinary 
networking activities. These include 
academic-to-academic networking; 
academic-to-industry networking; and a 
number of supporting activities. A pan-UK 
network could bring together the work of 
the seven previous networks under a 
common umbrella. This would provide a 
Theme 1:  
Foundational science and engineering
Bacterial logic gates
Professors Richard Kitney and Martin Buck (Imperial College London) have 
demonstrated that we can build ‘logic gates’, like those used for processing information 
in computers and microprocessors, out of harmless gut bacteria and DNA. Logic gates 
are fundamental building blocks in silicon circuitry. The researchers have replicated 
these logic gates using biological parts and showed that they behaved like their 
electronic counterparts. The new biological gates are also modular, which means that 
they can be fitted together to make different types of logic gates, paving the way for 
more complex biological processors to be built in the future. 
13  www.epsrc.ac.uk/newsevents/news/2012/Pages/
syntheticbiology.aspx
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forum for the research centres, as well as 
smaller research groups in other institutions, 
to discuss a range of topics, exchange 
best practice and act as a showcase for 
the presentation of work with applications 
in a range of industry sectors. It is 
envisaged that the network should use 
traditional formats and virtual 
communication, such as social 
networking, to build an integrated synthetic 
biology community. The plant sciences 
‘GARNET’ model14 provides an example of 
a pan-UK network that undertakes tasks 
that mirror those required in synthetic 
biology. As discussed under theme 3, 
these networking concepts could be taken 
forward by the recently formed special 
interest group (SIG).
Training
The UK has been very proactive in the 
area of education and training relating to 
synthetic biology over a number of years. 
For example, in the session on education 
and training at the Fourth International 
Meeting on Synthetic Biology (SB4.0), UK 
universities were singled out (along with 
some US universities) as leaders in this 
area. This activity has taken a number of 
forms. There are now a number of 
programmes in operation. These include 
undergraduate final-year options, MScs 
and MRes/PhD programmes. In addition, 
UK teams have been highly successful at 
iGEM15 (an international undergraduate 
competition) over a number of years. 
There may now be a need to streamline 
the existing education and training 
programmes and, where appropriate, to 
introduce new courses to address the 
industrial translation process and, more 
generally, to meet the needs of industry. 
It is important to recognise that specialist 
training is required to produce 
professional, responsible synthetic biology 
researchers. The road mapping 
workshops identified the need to build, 
maintain and develop the skills base and 
to enhance interdisciplinary graduate 
training. It is also important to recognise 
that synthetic biology training and 
education needs to take place at all levels 
– from school outreach (potentially 
including more practical engagement and 
learning, as for example being promoted 
elsewhere via iGEM High School16) to 
undergraduate and postgraduate training 
and beyond – and that mechanisms need 
to be tailored to meet the needs of specific 
student groups. Hands-on experience of 
synthetic biology should start at the 
undergraduate level with taught modules 
given by teams of research-active staff 
with direct experience of ‘wet-lab’ biology, 
engineering design and modelling, and 
expertise in the ethical and societal 
aspects of synthetic biology. Such courses 
should attract students drawn from a 
number of disciplines, for example biology, 
engineering and chemistry. 
Postgraduate training must be intrinsically 
multidisciplinary. In addition to the 
experience derived from existing 
programmes in synthetic biology around 
the world, it is important to learn from 
programmes in associated areas, for 
example, systems biology. Suitable 
students should be identified to study at, 
or in association with, the research 
centres. In this regard, it should be noted 
that many of the most successful research 
centres in synthetic biology around the 
world have, from their inception, included 
a multidisciplinary training environment. 
Students should follow the one-year MRes 
plus three-year research project model 
that has been very successful in a number 
of areas. The approach also includes 
cross-disciplinary co-supervision, together 
with professional internships within UK 
companies and summer schools. In 
addition, students should be educated in 
societal and ethical issues, and 
opportunities for technical and 
management training should be explored. 
Short courses for existing industrial 
personnel should be envisaged.
Any course in synthetic biology will have a 
high content of engineering and physical 
science. Hence, synthetic biologists 
aiming to practise in industry may benefit 
from professional as well as academic 
qualifications (compare chartered status in 
engineering). Accreditation of courses, in 
this context, would be carried out by the 
appropriate professional institutions (for 
example, the Institute of Engineering and 
Technology).
14 See www.garnetcommunity.org.uk/
15 See http://igem.org/Main_Page
16  iGEM High School is now in its second year and 
expanding internationally: http://igem.org/High_
School_Division
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Theme 2:  
Continuing responsible research and innovation 
It is crucial that this technology 
continues to be developed in a 
socially responsible fashion, and that 
relevant stakeholders, regulators and 
the public are engaged in research 
and innovation processes from the 
outset. Responsible research and 
innovation encompasses, but is not 
confined to, operating within an 
effective risk regulatory framework. 
The UK needs to be, and to be seen to 
be, leading the way in frameworks and 
methodologies for responsible 
innovation. The UK has already 
initiated public dialogue in synthetic 
biology and encouraged interaction 
between regulators and funders. 
Since synthetic biology is a new field, there 
is much uncertainty surrounding both the 
risks and benefits of its research and 
applications. While stringent risk 
management is crucial for responsible 
research and innovation, inescapable 
uncertainty must be acknowledged and 
accounted for. The aim of responsible 
research and innovation is not simply to 
predict and proactively manage negative 
outcomes, but also to shape decision-
making procedures that recognise such 
uncertainty across the whole life cycle of 
innovation. To foster successful innovation, 
governance must be flexible, transparent, 
open to wider participation, and 
responsive to emerging evidence and 
changing social priorities.
Public acceptability 
Public acceptability is widely recognised 
as a crucial issue for synthetic biology, but 
it cannot be adequately dealt with through 
communication aimed at reassuring the 
public. Prior public controversies on 
emerging technologies demonstrate that it 
is essential for debates to go beyond the 
community of experts to open up 
discussions about the purpose of innovation 
and about uncertainties and complexities 
surrounding both the benefits and risks 
associated with particular applications. 
Research has shown that ‘the public’ is not 
a singular pre-existing mass that accepts or 
rejects particular technologies according to 
fixed preconceptions. The direction taken 
by innovation pathways, and their perceived 
social consequences, themselves shape 
public responses. The responses and 
decisions of many and varied social 
groups – alongside those of academic 
researchers and firms – help to determine 
technological pathways and the realisation 
of benefits. These include institutions 
involved in health, safety and environmental 
regulation, intellectual property, research 
funding, and capital investment, as well as 
intended users and beneficiaries, and civil 
society groups. New social groups also 
emerge alongside innovation (new 
pressure groups may come into being 
when, for example, a new drug is 
developed to extend the life of patients 
with a specific terminal cancer). All of 
these groups need to be actively engaged, 
throughout the process, in the governance 
of synthetic biology research and innovation.
In the UK, public acceptability was 
recognised as crucial from an early stage 
and led to a large-scale synthetic biology 
dialogue in 2010. Findings from the dialogue 
showed there was support for synthetic 
biology but that this was conditional. While 
there was great enthusiasm for the 
possibilities of the science and its application, 
there were also fears of control and misuse 
and concerns about how to govern this 
novel area when there is uncertainty over 
its outcomes. One of the key findings of 
the dialogue – which is consistent with a 
large body of social science research – 
was the emergence of these five key 
questions that synthetic biologists should 
be willing and able to answer17:
•	 what	is	the	purpose?
•	 why	do	you	want	to	do	it?
•	 what	are	you	going	to	gain	from	it?
•	 what	else	is	it	going	to	do?
•	 how	do	you	know	you	are	right?
To build on this successful dialogue, it is 
crucial that these questions are at the 
forefront of ongoing decisions about the 
commercialisation, translation and 
regulation of synthetic biology. Indeed, 
BBSRC, on behalf of the UK research 
councils, posed those questions in the 
closing session of the Six-Academy 
Synthetic Biology Symposium II in 
Shanghai in October 201118. Although 
addressing health, environmental and 
security risks is important, this will not in 
itself lead to broad public acceptability 
unless innovation in synthetic biology is 
demonstrably directed towards:
•	 new	products,	processes	and	services	
that can bring clear public benefits 
including, but not limited to, 
employment, improved quality of life 
and economic growth
•	 solutions	to	compelling	problems	that	
are more effective, safer and/or cheaper 
than existing (or alternative) solutions.
Integrating social sciences, humanities 
and arts researchers can help with 
understanding of, and engagement with, 
such issues and thus foster responsible 
innovation. The UK is at the forefront of 
experimenting with such cross-domain 
collaborations: the seven synthetic biology 
networks included social scientists, artists, 
philosophers, and legal scholars; and the 
Imperial College Centre for Synthetic 
Biology and Innovation (CSynBI) was set 
up as a joint centre between scientists and 
engineers at Imperial College and social 
scientists at the BIOS research group19. 
18 Six Academies Synthetic Biology Symposium II 
– Shanghai 12 – 14 October 2011, www.sibs.ac.cn/
synbio/programme.asp 
19  BIOS – a centre for Biological Sciences originally based 
at the London School of Economics (LSE) and now 
based in King’s College London 
17  BBSRC/EPSRC (2010) Synthetic Biology Dialogue. 
Swindon, Biotechnology and Biological Sciences 
Research Council (BBSRC) and the Engineering and 
Physical Sciences Research Council (EPSRC), p.7. 
Online at: www.bbsrc.ac.uk/web/FILES/Reviews/1006-
synthetic-biology-dialogue.pdf 
For a summary of how these same issues recur 
throughout all the ScienceWise Dialogues, see Chilvers, 
J and Macnaghten, P. (2011) The Future of Science 
Governance: A review of public concerns, governance 
and institutional response. London: Sciencewise-ERC. 
Online at www.sciencewise-erc.org.uk 
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Regulating synthetic biology
Building a culture of responsibility, 
evaluating health and environmental risks 
at all stages from the planning stage 
onwards, and increasing awareness of 
those risks are integral to good practice in 
synthetic biology research and innovation 
and in the subsequent development of 
synthetic biology products, processes and 
services. Regulatory authorities recognise 
that synthetic organisms may have 
unintended harmful consequences; in 
certain circumstances they could transfer 
DNA to other organisms, and unanticipated 
interactions between synthetic organisms 
and the environment or other organisms 
could cause unintended harm to the 
environment and public health. Such risks 
are currently covered by relevant 
conventions and legislation, and active 
review processes exist to ensure these 
remain informed by, and responsive to, 
emerging developments in synthetic 
biology. Biosecurity issues also arise from 
the risk of deliberate actions intended to 
cause harm by people who pay no heed to 
legislative regulations. Additional measures 
may be required for such scenarios and 
these have been seriously considered in 
numerous studies in recent years20,21.
At present, synthetic biology is regulated 
by conventions and legislation that was 
established to regulate the use of 
genetically modified organisms (GMOs). 
Regulations for the ‘contained use’ and 
‘deliberate release to the environment’ of 
GMOs are determined at the EU level 
through directives which are then 
transcribed into UK law. In the future, 
certain applications of synthetic biology 
could conceivably entail the deliberate 
release of modified organisms to the 
environment. If this were to be the case, 
the legislation relating to the deliberate 
release of GMOs would apply. Under this 
system, decisions on research trials are 
made at the national level, whereas 
decisions on marketing applications are 
made at the EU level. Currently there are 
some problems with the operation of the 
EU clearance processes, and this could 
act as a barrier to commercialisation of 
certain synthetic biology products. The UK 
government is currently engaged in EU 
negotiations with the aim of enabling more 
effective operation of the current regulatory 
system. The Cartagena Protocol on 
Biosafety to the Convention on Biological 
Diversity is an international agreement 
which aims to ensure the safe handling, 
transport and use of living modified 
organisms (LMOs) resulting from modern 
biotechnology that may have adverse 
effects on biological diversity, taking also 
into account risks to human health22. There 
are 163 countries party to the Cartagena 
Protocol, including the UK.
Work in research laboratories involving the 
genetic manipulation of organisms is 
required to comply with Contained Use 
Regulations23. All persons carrying out 
such work must notify the Health and 
Safety Executive (HSE), and for higher risk 
work must have consent before they 
proceed. The controls required are based 
on an assessment of the risks of potential 
for harm to human health and for damage 
to the environment. Any work with a 
substance produced by synthetic biology 
processes, which is not itself a genetically 
modified organism, but is potentially 
hazardous to human health (for example 
toxic or allergenic), would require risk 
assessment and appropriate controls to 
protect the workers and any other persons 
who might be affected24.
Regulations are kept under constant 
review by the regulators, be they the HSE 
Public dialogue on synthetic biology
Synthetic biology has enormous potential but also raises questions around ethics, 
social justice and biosecurity. In 2010, the Biotechnology and Biological Sciences 
Research Council (BBSRC) and the Engineering and Physical Sciences Research 
Council (EPSRC) published the results of a joint public dialogue on synthetic biology 
(with support from Sciencewise-ERC, the UK’s national centre for public dialogue in 
policy-making involving science and technology issues). 
The dialogue explored people’s hopes and fears for synthetic biology, aiming to  
ensure that the research funded by the two councils sits comfortably with society.  
Four workshops in England, Scotland and Wales were attended by 160 members of 
the public. An additional 41 interviews were carried out with consumer groups, industry 
and scientists, focusing on the issues and the development of the science. The 
dialogue revealed that most people are supportive of the research but with conditions 
on how and why it is conducted. The results of the dialogue have influenced how 
BBSRC and EPSRC think about funding research in synthetic biology.
20  NIH Guidelines for Research Involving Recombinant 
DNA Molecules
21  Addressing biosecurity concerns related to Synthetic 
Biology: Report of the National Science Advisory Board 
for Biosecurity (NSABB), April 2010
23  Directive 2009/41/EC on the contained use of 
genetically modified micro-organisms; GMO 
(Contained Use) Regulations 2000
24  The Control of Substances Hazardous to Health 
Regulations 2002.22  http://bch.cbd.int/protocol/
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or the Home Office, recognising that 
science continues to develop and 
regulation needs to reflect those changes. 
The principles underlying current 
regulations are that they:
•	 place	the	protection	of	human	health	
and prevention of harm to the 
environment as the first priority
•	 take	a	risk-based	approach,	requiring	
proportionately more stringent controls 
for higher hazard work
•	 allow	novel	work	to	be	carried	out,	
without unduly hindering innovation, but 
for GM work require that risk 
assessments are reviewed and for 
higher-risk work that the regulator gives 
consent before the work begins.
Questions have been raised about the 
extent to which the risk assessment 
framework for genetically modified 
organisms will be appropriate for synthetic 
biology (due, for example, to the larger 
number of genes transferred and the 
possible use of synthetic genes with no 
wild-type comparator)25. The current 
general consensus among regulators and 
scientific institutions is that existing GM 
regulations are broadly adequate and 
could be adapted for synthetic biology, but 
that regulators need to keep a watching 
brief as synthetic biology research develops.
The regulatory framework for the release of 
genetically engineered organisms remains 
contested, most visibly in Europe, but also 
in the United States and around the world, 
albeit relating to technologies that precede 
and are different from synthetic biology. What 
is contested is not so much ‘Is it risky or not?’ 
but rather: ‘What counts as risk?’ and ‘Who 
decides?’ It will be crucial, as synthetic 
biology progresses, to continue developing 
a robust regulatory and enforcement regime 
involving scrutiny, evaluation and modification 
of existing regulations to address issues 
such as indirect, delayed, and cumulative 
long-term effects, including accumulated 
effects of approvals for different organisms; 
and appraisal of risks which consider how 
the technology will be used in practice, in 
real-world conditions. The latter includes the 
potential for ‘dual use’ at a time of increasing 
global uncertainty. (Science is primarily used 
to benefit humanity, but particular scientific 
technologies can be misused, presenting 
scientists and others with an ethical quandary 
known as the dual-use dilemma26.) It is 
also essential to ensure that a broad range 
of scientific experts and other stakeholders 
continue to be involved in scrutinising and 
contributing to the questions asked in risk 
assessments. This must include international 
collaboration, which will be essential to 
allow the UK to realise the full benefits of 
its synthetic biology sector. 
In addition, in order to ensure that the spirit 
and not just the letter of the legislation is 
followed, it is important that researchers 
and regulators work together to ensure 
that all novel entities and methods 
produced through synthetic biology are 
encompassed by these GMO regulations, 
or are replaced with alternative legislation 
providing appropriate risk safeguards. 
In summary, responsible research and 
innovation for synthetic biology requires:
•	 that	inescapable	uncertainty	is	
acknowledged and measures are put in 
place to ensure safe, rapid and effective 
responses to any unforeseen problems
•	 that	the	UK	maintains	and	develops	its	
regulatory and enforcement regime 
for environmental, health and security 
risks relating to synthetic biology and 
that it does so from an international 
perspective
•	 that	‘engagement’	means	genuinely	
giving power to a wide range of diverse 
social groups, including those who  
will be the end users or presumed 
beneficiaries of the technologies,  
taking their concerns seriously, and 
enabling them to participate throughout 
the whole pathway of technological 
development.
Checks and balances
The Biotechnology and Biological Sciences Research Council (BBSRC) has a number 
of checks and balances in place to ensure that the researchers it funds are aware of 
any ethical and social issues that their research raises, and that they respond to these 
appropriately. Applicants are required to consider the ethical issues raised by their 
grants, for instance, the need to use animals in an experiment or the potential for 
misuse. If any issues are identified by the peer reviewers or grant committees then 
BBSRC can draw on a broad range of expertise via its Bioscience and Society Strategy 
panel and from third parties like the National Centre for the Replacement, Refinement 
and Reduction of Animals in Research (NC3Rs). BBSRC will not start paying grants 
until all issues have been resolved.
26  Rodemeyer, M (2009) New Life, Old Bottles: Regulating 
First-Generation Products of Synthetic Biology Woodrow 
Wilson International Center for Scholars; Dana GV, 
Kuiken T, Rejeski D, et al. Synthetic biology: Four steps 
to avoid a synthetic-biology disaster. Nature 2012 
483(7387): 29. 
26  Parliamentary Office of Science and Technology, 
Postnote, July 2009, Number 340
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In this third thematic area we consider 
how to advance synthetic biology 
technologies so that they are fit for use 
in a broad range of potential 
applications and markets. Implicit in 
this activity is the desire to increase 
growth in the UK economy, generating 
wealth and creating jobs, consistent 
with the ongoing practice of responsible 
research and innovation outlined in 
theme 2. Below, we set out some of 
the opportunities available in the UK 
to accelerate the development and 
uptake of this powerful technology. 
The work draws on the overarching 
framework of the Technology Strategy 
Board’s Emerging Technologies and 
Industries Strategy, other roadmaps 
and literature, sector expertise and 
the outputs of the two roadmapping 
workshops. A key element is the 
iterative process of matching the 
commercial requirements of a number 
of potential markets to the 
performance that is, or could be, 
achieved by the technology.
Synthetic biology is still at a relatively early 
stage of emerging from the science base, 
but it has truly disruptive potential. Already 
it allows some things to be done that were 
not previously possible. Many more things 
will follow. Even now it is beginning to offer 
totally new opportunities for existing 
businesses and new entrants. Below are 
some of the ways in which those 
opportunities can best be realised. 
Seeing the opportunity
The UK possesses outstanding expertise 
in its science and engineering base as well 
as imaginative businesses that are both 
well established and newly formed. The 
science is rapidly advancing and markets 
are changing almost as quickly. This is 
true, not just in the core synthetic biology 
technologies, but also in the supporting 
technologies such as rapid sequencing, 
microfluidics and bioCAD. It can be 
difficult for individuals in businesses to 
stay abreast of scientific developments 
across the entire field and to determine 
how these can be best applied to the 
opportunities they see in their own 
organisations and markets. No individual 
or group of individuals is likely to be fully 
aware of all of the most promising 
business opportunities. An opportunity 
exists, therefore, to bring those at the 
cutting edge of science together with 
innovators in business to find the best fit 
between commercial opportunity and 
scientific potential, and to help them to 
work together to develop their ideas: to 
energise the new product supply chain, 
and to inform the science base.
Creating the industrial 
translation process
Synthetic biology is, by definition, an 
applied approach. It draws on a range of 
fundamental fields in the life sciences, as 
described in the synthetic biology section 
and outlined in figure 4. The industrial 
translation process takes the idea through 
a development process from laboratory to 
market, as schematically captured in figure 
5. Output from the initial science and 
engineering phase may take any of a wide 
range of forms, such as newly characterised 
bioparts within the registry, new industrial 
hosts or chassis, or new assembly methods. 
The next step in the translation process is 
the development of the industrial 
engineering methods appropriate for the 
applications being developed, and 
ultimately the development of biofactories. 
All of the stages in the translation process 
lead through to products and, ultimately,  
to market. It is essential to develop 
processes whereby industrialists and 
academic researchers can more 
effectively collaborate to define application 
projects and requirements in terms of 
industrial techniques and the market, 
including societal benefits. These 
collaborations are likely to be different in 
relation to projects with large companies 
and projects with SMEs. 
Accelerating the journey  
to market
Most modern technological products and 
services exist in complex, and global, 
supply chains, and it takes time to 
introduce and have adopted radically 
different propositions. Each organisation 
along the chain has to evaluate the impact 
a new technology may have on its 
operations, and has to satisfy itself that it 
can assure the quality and delivery of the 
commercial offering. It has been shown 
that one of the best ways to speed up this 
process is to create ’demonstrators’ that 
show what is on offer in a compelling 
way27. Helping innovating organisations to 
produce demonstrators of various kinds 
will advance the technology more quickly 
to market. In some cases the type of 
demonstration needed will be 
demonstration of scale, and access to 
production capability to assist scale-up 
will be important. Some of the facilities 
needed already exist in the UK. In other 
cases, demonstration will require access 
to cutting-edge laboratory equipment, and 
it is important that critical equipment is 
located within the UK – it should be made 
easier for businesses to access the 
expertise and facilities within the university 
sector. This could be particularly valuable 
in highly specialised areas or where a 
combination of biology and electronics or 
material sciences is used.
Reducing the commercial  
and technical risk
It is a regrettable fact that new product 
introductions often fail, even where the 
products themselves can deliver benefits 
for consumers and have economic 
potential28,29. A proven method of bringing 
more products to market sooner is to help 
Theme 3:  
Developing technology for commercial use
27  Technology Strategy Board, Emerging Technologies 
and Industries Strategy 2010-13 (Feb 2010)  
www.innovateuk.org see under publications/strategy
28  Source: Stevens, G.A. and Burley, J., 3,000 Raw Ideas 
= 1 Commercial Success!,(May/June 1997) Research 
Technology Management, Vol. 40, #3, pp. 16-27.
29  Robert G Cooper, Winning at New Products, 3rd Edition, 
p10-12 (Basic Books, 2001)
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reduce the risk of technical failure, and to 
share the financial risk. This can be done 
by bringing people from different 
organisations and with different capabilities 
together to work jointly on collaborative 
projects. These organisations can find 
better solutions to problems, and share the 
research and development costs, reducing 
the burden on any individual one of them. 
In the next stages of the development of 
synthetic biology, whilst companies may 
perceive that there is little or no technical 
risk in specific project areas, they certainly 
perceive that there is commercial risk. 
A three-component approach, comprising 
input in both cash and kind, has been 
found to be effective. The three 
components of this hybrid model are 
industrial resources, public resources and 
university resources. The public funding 
contribution would normally be in terms of 
cash or the de-risking of the investment to 
make it more attractive to other potential 
funders (such as venture capitalists). The 
main university contribution is in terms of 
research facilities and highly skilled 
research personnel. Industry may 
contribute cash or know-how. The public 
and university components of the model 
act as a catalyst to counteract common 
causes of failure of application projects as 
seen from industry, for example through 
provision of training, mentoring and 
expansion of partnering opportunities. 
Larger industries may also separately fund 
their own ‘in-house’ research to address 
their internal investment criteria.
In his keynote speech at the University of 
East Anglia ‘What’s the Good of 
Government?’30 the Minister of State for 
Universities and Science David Willetts 
said: ‘The Government can bear the big 
risks of scientific innovation, which are too 
great for any individual company.’ This is 
not to be interpreted as being an argument 
for a ‘blank cheque’ from government for 
innovative companies, but it does highlight 
the potential for government to be an early 
adopter and to stimulate demand for 
potentially valuable innovations that initially 
entail a high degree of risk. One such 
mechanism potentially available to 
government might be use of the Small 
Business Research Initiative (SBRI) scheme. 
SBRI could be used to procure synthetic 
biology developments that potentially 
meet the strategic and operational needs 
of government departments and the 
interests of society that they serve whilst 
simultaneously serving to de-risk 
commercial developments for emerging 
private sector customers – thereby 
creating new commercial markets as well. 
BIS has increased the funding for SBRI 
through the package of support for SMEs 
announced in the Innovation and 
Research Strategy31 to be delivered 
through the Technology Strategy Board. 
Since the launch of the programme in 
2009, SBRI has awarded 914 contracts 
worth £78m to technology based SMEs. 
Some 55 per cent of these contracts have 
been awarded to either micro (fewer than 
10 employees) or small (fewer than 50 
employees) companies, typically the sort of 
companies that the public sector has the 
greatest difficulty in contracting with. The 
additional funding is expected to enable 
the Government to build on this success, 
and promote awareness and take-up of 
SBRI across departments. Synthetic 
biology could be considered a candidate 
technology for the future use of the SBRI 
approach32.
Building a community  
of practitioners
The UK has numerous well established 
networks in the academic and business 
domains, and these have much to 
contribute to a community of practice in 
this space. Complex problems are often 
best addressed by bringing a combination 
of experienced and fresh minds to bear on 
the topic. Applying a variety of mechanisms 
to build a networked community will be 
particularly important in synthetic biology 
because of the wide range of disciplines 
involved – science, engineering, social, 
regulatory and others – and the need to 
develop common standards and protocols.
Creating momentum –  
critical mass
When businesses cluster together they can 
collectively be more effective. Examples 
from the digital industry are well known 
and include Silicon Valley, Silicon Fen, and 
Tech City. With today’s communications it 
is no longer essential for clustering 
businesses to be located together, but 
providing a nucleus for the activities of 
various protagonists can add value. The 
UK is fortunate in that three of the world’s 
top 10 life sciences universities (Cambridge, 
Oxford, Imperial) are relatively close 
geographically and, indeed, the span of 
Biotica/Amyris: from therapeutics to renewable fuels
Polyketides are compounds from bacteria and fungi that hold great promise in areas 
ranging from clinical medicine to biofuels. Biotica, a company co-founded by Professor 
Peter Leadley, of the University of Cambridge, has signed a non-exclusive deal with 
Amyris, an integrated renewable products company, that will see Amyris use Biotica’s 
polyketide engineering technology to make a range of compounds that are either 
difficult or impossible to make by conventional methods. The agreement between 
Biotica and Amyris could bring new routes to renewable fuels a step closer. 
30  See www.bis.gov.uk/news/speeches/david-willetts-
whats-the-good-of-government-2012
31  See www.bis.gov.uk/assets/biscore/innovation/docs/i/ 
11-1387-innovation-and-research-strategy-for-growth.pdf
32  See www.innovateuk.org under publications/about our 
programmes
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academic establishments working in 
synthetic biology and related disciplines 
across the UK as a whole is relatively 
compact.
A characteristic of synthetic biology is the 
need for multidisciplinary centres. 
Establishing a UK-wide network of 
academic, industrial and other organisational 
interests will benefit from the presence of a 
backbone of potentially several 
multidisciplinary centres, including an 
innovation and knowledge centre (IKC) for 
synthetic biology. Reviewing the options 
and proposing an optimum configuration 
for the UK is a clear requirement emerging 
from this roadmap. 
Intellectual property
The way in which intellectual property (IP) 
rights are treated will play an important role 
in encouraging the development of 
synthetic biology in the UK. At a fundamental 
level, the concept of ‘ownership’ of living 
organisms raises ethical issues that are 
approached differently in different territories. 
At a technology level, there is a balance to 
be struck between that which may 
reasonably be protected and that which 
would encourage greater enterprise 
through being made available as open 
source. The BioBricks Foundation33 
represent this latter approach, seeking to 
ensure that standard biological parts they 
create are made freely available in the 
public domain. Conversely, it is also 
recognised that the formation of a fully 
reliable and characterised library of parts 
will require significant investment that may 
reasonably justify a level of intellectual 
property protection. Related issues arise 
when considering more complex entities 
assembled from these basic parts such as 
devices and systems. Finding where to 
draw the line between what is publicly 
available and what is protected by IP 
remains a subject of ongoing debate. 
Nevertheless, there is clearly a regime in 
which specific applications are developed, 
optimised and commercialised for which 
IP ownership will be vitally important. It is 
vital to establish an appropriate and more 
consistent approach to determining what 
is, or is not, suitable as a basis for 
protection as intellectual property in this 
field of synthetic biology. To be broadly 
useful and effective, this will need to be 
addressed at an international level.
We have identified the importance of 
improved academic/industrial partnerships, 
and indeed the links between different 
scales of industry in developing synthetic 
biology in the UK. Establishing suitable 
mechanisms for IP capture and ownership 
will be highly influential in promoting the 
desired working environment. A common 
approach is to consider the development 
of ideas sequentially, capturing IP along 
the pathway and, for example, if the 
patentable idea is developed within 
academia, to consider translation to industry 
via licensing (compare the Lambert 
Review model from 200334). Alternatively, 
taking the more integrated approach we 
have explored in this roadmap, it is clear 
that industry plays a significant role in 
helping identify and access end markets, 
and in so doing may help shape and focus 
the early-stage and application development 
processes. The recent ‘patent-box’ 
initiative, which provides a tax break for 
corporate income earned through the 
exploitation of a patented invention, 
provides a strong incentive to industries to 
get more involved in the development of 
qualifying IP within the UK, and has 
already had an important influence on the 
recent decision by GlaxoSmithKline to 
increase their investments in the UK35. 
Important technologies  
for development
It will be important to invest in the 
development of technologies that work 
across a wide range of applications. This 
will include the development of accurate 
and reliable characterisation methods for 
defining bioparts and the development of 
different types of hosts or chassis (ie cells 
used in the synthetic biology process). 
Particularly relevant here is the 
development of new industrial strains of 
hosts. New wet-lab assembly techniques 
will need to be optimised for industrial 
application. Biopart characterisation, host 
development and assembly methods 
could be incorporated within a web-based 
information environment containing 
bioCAD tools, a registry of bioparts (with 
their associated metadata) and a registry 
of models. Industrial engineering methods, 
applicable to the specific applications, will 
need to be developed, leading ultimately 
to the development of biofactories. 
Amyris: anti-malarials and more
Amyris is a US-based company that is using synthetic biology to produce high-
performing alternatives to oil-based fuels and chemicals. Amyris was founded in 2003 
by four post-doctoral researchers from the University of California Berkeley. Their 
founding product was Artemisinin, a highly effective anti-malarial medicine traditionally 
derived from plants using a slow and expensive process. The Amyris team used 
synthetic biology to engineer the pathway for producing an Artemisinin precursor in 
yeast which could then be converted into the drug relatively easily. Amyris granted a 
royalty-free licence for the technology to Sanofi-aventis to develop the production 
process to a commercial scale. Using building-blocks derived from its yeast-based 
platform and renewable feedstocks, Amyris is now developing a slate of different 
products for the fuels and specialist chemicals markets.
33 http://biobricks.org/
34  www.hm-treasury.gov.uk/lambert_review_business_
university_collab.htm
35  www.gsk.com/media/pressreleases/2012/2012-
pressrelease-994808.htm
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One of the exciting things about 
synthetic biology is the wide range of 
applications to which it might be put. 
Its potential is truly as a platform 
technology, capable of realising 
benefit in a very wide range of 
markets. The full breadth of 
applications is clearly articulated in 
the literature and was reinforced by 
the workshops we held. Below is a 
summary of some of the key 
opportunities that have been identified 
and from which the UK is well placed 
to benefit. Many of these benefits 
could be realised using renewable and 
potentially low-carbon biological 
materials.
Medicines and healthcare
An increasing proportion, currently an 
estimated 20% (up from 10% in 200236),  
of all medicines are biopharmaceuticals 
– in which the active pharmaceutical 
ingredient (API) is a large biological 
molecule, such as a protein (as in insulin) 
rather than a small molecule (as in aspirin). 
Such large and complex molecules can be 
very difficult and/or expensive to extract 
from natural plant materials or make using 
conventional chemical processes. 
Synthetic biology has the potential for a 
step-change reduction in the difficulty of 
production, potentially making expensive 
drugs, both biopharmaceuticals and small 
molecule APIs, more available to patients, 
and also benefiting the industry. BCC 
Research identify around 20 drugs based 
on the use of synthetic biology that are 
currently under development or clinical 
evaluation37. We know of others. Cells 
could potentially be designed for use as 
therapeutic agents to deliver delicate drug 
molecules (that would otherwise be 
metabolised by the body before reaching 
the diseased area) in a targeted way. It is 
even possible to envisage the use of a cell 
as a biosensor to detect a biomarker for a 
disease and then, from within the same cell, 
to switch on the production of a desired 
drug. If brought to fruition, this could truly 
revolutionise the treatment of chronic 
illness. Other applications include vaccines 
and gene therapies. Synthetic biology 
technologies could also be used as enabling 
tools to help researchers identify and 
interrupt disease pathways more quickly.
Fine and speciality chemicals
Although it is not possible in all cases now, 
the technology has the theoretical potential 
to produce many of the chemicals or 
materials currently derived from 
petrochemical feedstocks using 
fermentation/industrial biotechnology 
routes and renewable feedstocks. 
Industrial biotechnology could be a key 
application area for synthetic biology, 
providing the platform to deliver benefits to 
many different sectors. Potential applications 
include cosmetics, flavours, fragrances, 
lubricants, additives, polymers and 
rubbers, surfactants, biopharmaceuticals 
and detergents. In some cases, synthetic 
biology may already provide advantages 
over existing routes, and, in the longer 
term, alternative routes to materials 
currently derived from fossil hydrocarbons 
may become increasingly attractive.
In the short to medium term, industrial 
biotechnology is an area that could derive 
particular benefit from synthetic biology, 
with opportunities for economic growth. To 
help drive this process, it will be important 
for the Industrial Biotechnology Leadership 
Forum and the Synthetic Biology 
Leadership Council to ensure their work is 
aligned.
Energy
The production of biofuels using biological 
conversion processes is well established. 
Bioethanol is the product of fermentation 
by yeast. In addition to yeast, a variety of 
different micro-organisms, including 
bacteria and cyanobacteria, are being 
investigated for fuel component 
production capabilities. Modification of 
such organisms to improve production 
economics or to produce different fuel or 
chemical component characteristics is 
being explored by many universities and 
companies, for example modifying yeast 
to produce iso-butanol38, or farnasene39, 
whilst engineered clostridia may be used 
in the industrial production of n-butanol40. 
Longer-term options include direct 
conversion of sunlight to fuels such as 
hydrogen. Such ‘solar fuels’, produced via 
‘artificial photosynthesis’, may be achieved 
using entirely inorganic materials, or by 
applying synthetic biology to produce 
Theme 4:  
Applications and markets 
TMO Renewables
One of the cornerstones of the TMO process is the ability of its proprietary 
microorganisms to produce ethanol from a wide range of non-food lignocellulosic 
feedstocks. TMO has achieved this by employing a synthetic biology approach to 
develop strains that can convert such feedstocks to fermentable sugars with greater 
efficiency, thus maximising ethanol yields and lowering one of the economic barriers 
that previously restricted the manufacture of cellulosic ethanol. Using synthetic biology 
techniques will facilitate the development of additional improved strains for use in the 
production of other renewable fuels and chemicals. 
36  EvaluatePharma World Preview 2016: Beyond The 
Patent Cliff, p8 (June 2011)
37  BCC Research, Synthetic Biology: Emerging Global 
Markets. November 2011.
38  Gevo: http://blogs.nature.com/news/2012/05/
butanol-hits-the-biofuels-big-time.html
39  Amyris: Renewable Chemicals Digest, 25 June 2010.
40 Green Biologics: www.greenbiologics.com/ 
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some form of hybrid system. Such an 
approach would have the benefits of direct 
photon capture, with the captured energy 
stored in chemical bonds via conversion of 
water or carbon dioxide. A number of 
academic groups in the UK are working in 
this field, including Imperial College and 
Glasgow (see box)41. 
Environmental
Synthetic biology technologies could be 
useful in bioremediation42, for the digestion 
of otherwise difficult to dispose of 
materials, or for the absorption and 
retention of impurities, such as arsenic or 
radioactive elements, in water. It could 
become possible to mine waste streams 
using novel organisms to seek out, and 
concentrate up, rare elements from 
distributed sources such as waste effluent 
streams or landfill. The technology could 
also find application in CO2 capture.
Sensors
Biological systems can be highly sensitive 
and can detect extremely low levels of 
target substances with extremely high 
selectivity and specificity43. This fact could 
be used to design sensor systems that 
could be used in healthcare applications 
to detect the early stages of time-critical 
conditions such as sepsis, or to give early 
warning of the presence of undesirable 
bacteria, viruses or other pathogens or 
poisons. They may also be used to check 
for contamination of drinking water, for 
example by arsenic44.
Agriculture and food
Agriculture is a powerful route for 
producing large volumes of biological 
materials (such as for food, clothing or 
paper) or smaller compounds (such as 
sugar). Synthetic biology has the potential 
to make food crops less vulnerable to 
stresses such as drought, saline water or 
pests and diseases; and/or to create new 
plants that can produce, in the field, large 
volumes of substances useful to man. 
Core and underpinning 
technologies
In addition to the synthetic-biology-derived 
products mentioned above, a thriving 
industry would have to draw upon a range 
of core and underpinning technologies 
such as DNA design, DNA synthesis, rapid 
sequencing, bioparts, microfluidics, 
enzyme evolution or other manufacturing 
technologies, and bioCAD or other ICT 
tools. Technology development in these 
areas could itself provide a basis for 
possible new industries, with DNA 
sequencing an example of a successful UK 
development in underpinning technology.
The global value of these combined 
markets has been estimated by BCC to be 
$10.8bn by 201645, up from $1.6bn in 2011. 
Products generated using synthetic 
biology techniques are expected to 
account for $9.5bn of this, with $1.3bn 
arising from the market for underpinning 
technologies.
The artificial leaf
Professor Richard Cogdell and Professor Lee Cronin (University of Glasgow) are taking 
a synthetic biology approach in a bid to create an artificial ‘leaf’ capable of converting 
the sun’s energy into a carbon-based liquid fuel. The researchers hope to use chemical 
reactions similar to photosynthesis but in an artificial system. Plants are able to take 
solar energy, concentrate it and use it to split apart water into hydrogen and oxygen. 
The oxygen is released and the hydrogen is locked into a fuel. Their research aims to 
use synthetic biology to replicate this process. 
41  Solar Fuels and Artificial Photosynthesis, Royal Society 
of Chemistry (www.rsc.org/solar-fuels) Jan 2012 
42  Victor de Lorenzo, Current Opinions in Biotechnology, 
2008, 19, 579.
43  Ahmed Khalil and James Collins, Nature Reviews 
Genetics 11, 367-379 (May 2010)
44  Development of a Set of Simple Bacterial Biosensors for 
Quantitative and Rapid Measurements of Arsenite and 
Arsenate in Potable Water. Stocker, J. et al. Environ. Sci. 
Technol, 2003, 37, 4743-4750
45  BCC Research, Synthetic Biology: Emerging Global 
Markets. November 2011. Summary: http://bccresearch.
blogspot.co.uk/2012/05/global-market-for-synthetic-
biology-to.html
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Theme 5:  
International cooperation
Realising the vision for synthetic 
biology should allow the UK to play a 
leading role in the international 
response to global challenges, 
including helping to set standards and 
suitable operating frameworks. In this 
way, the UK may reasonably seek to 
build on its current strengths and 
assume a leading international role in 
synthetic biology. 
Coordinated international 
cooperation
The UK is an important international player 
in synthetic biology through a major role in 
organising the Six-Academy Synthetic 
Biology Symposia. The six academies are 
the US’s National Academy of Science 
and National Academy of Engineering, 
the UK’s Royal Society and Royal 
Academy of Engineering, and the two 
equivalent Chinese academies. These 
meetings have played an important role  
in development and direction. We should 
continue to build upon the six academies 
initiative and at the national level seek 
further coordination between national 
learned societies with interest in the field 
(for example, the Biochemical Society,  
the Royal Society of Chemistry, Society  
for General Microbiology, the Institution  
of Engineering and Technology and the 
Institute of Physics). 
International collaboration should also be 
encouraged and supported through the 
research councils. Mechanisms such as 
‘ideas labs’ and ‘sandpits’46 joint with the 
US have been very successful at funding 
high-quality innovative science in synthetic 
biology. On a smaller scale, partnering 
awards have also been effective in seeding 
international collaborations. These 
mechanisms can be complemented by the 
work of the Foreign and Commonwealth 
Office (FCO), Science and Innovation 
Network and British Council funding 
scholarships and meetings. The FCO has 
a further role to play helping to promote 
UK science to foreign investors. We should 
aim to have a co-ordinated approach to 
international engagement, ensuring that 
we proactively engage partners to result in 
the greatest benefit to UK synthetic biology 
research and to UK plc. 
The UK academic community should 
continue to be very involved in the 
organisation of international conferences 
in synthetic biology (both in the UK and 
abroad). These may approach the subject 
from a variety of different perspectives,  
as exemplified by the enGENEious 
conference organised by students in June 
201247 through to plans for the UK to host 
the next (6th) international conference  
in synthetic biology (SB 6.0)48 in 2013.  
A UK–organised Gordon Conference in 
the field could have a strong impact. 
Engagement with international 
policy and funding bodies
Active engagement with international 
bodies will remain a very important 
element in the development of synthetic 
biology and in realising its potential. 
Despite a range of differences in 
approaches at national and regional 
levels, significant commonality also exists. 
Learning from this diversity of approaches, 
sharing best practice and seeking 
common standards where appropriate will 
all contribute positively towards the 
establishment of effective applications on 
a global scale. 
The question of intellectual property in 
synthetic biology should be discussed 
internationally, as it is not currently well 
defined. For this reason, there should be 
continued engagement with the 
Organisation for Economic Cooperation 
and Development. There should be 
encouragement of collaboration on 
studies relating to IP, in terms of 
industrialisation, as this is clearly an 
important issue. The patent situation for 
existing biological components and their 
use in research is in many cases unclear, 
and joint work would help to clarify this 
situation. The World Health Organisation 
should also be engaged in the areas of 
international healthcare, funding and 
governance. Joint work should be 
undertaken on regulations, ensuring a 
robust international regulatory framework 
for synthetic biology.
European (including UK) funders have 
collectively funded transnational projects 
in synthetic biology through the European 
Science Foundation EUROCORES 
initiative49. More recently, an ERA-NET in 
synthetic biology (ERASynBio) was 
launched50 which aims to enhance 
European synthetic biology by co-
ordinating national funders. The BBSRC 
has a strong role in the strategic 
development and infrastructure planning 
for this. The EU framework programme 
provides a route for large investments in 
synthetic biology. The next framework 
program, Horizon 2020, will provide in the 
region of P80m for European science with 
an emphasis on creating a knowledge 
based bioeconomy (KBBE), including a 
role for synthetic biology. This should  
be linked to the EU bioeconomy initiative.  
The UK should maintain its high 
involvement in the development of Horizon 
2020 to ensure appropriate support for 
synthetic biology research. 
Joint funding between the UK and US 
should continue to be explored and 
excellent collaborations and the networks 
generated through ideas labs and 
sandpits should continue to be supported. 
Opportunities to jointly fund with other 
non-EU countries leading on synthetic 
biology should also be explored. 
46  www.epsrc.ac.uk/newsevents/news/2009/Pages/
syntheticbiologysandpit.aspx
47 http://engeneious.chem.ox.ac.uk/
48 http://sb6.biobricks.org/
49 www.esf.org/activities/eurocores.html
50  http://netwatch.jrc.ec.europa.eu/nw/index.cfm/info/Net/
NetId/860D14FB0023C80D84EE1BBABCF12015
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Establishing international 
standards
The establishment of international 
standards is seen as an essential step in 
the translation/industrialisation process for 
synthetic biology, and some work is 
on-going in the UK, US and Europe, for 
example in relation to biocomponents.  
In the US, the technical standards work 
mainly revolves around synthetic biology 
open language (SBOL). The work under 
SBOL relates to the definition of DNA 
sequences and their unambiguous 
transmission. Another aspect of the work 
is to achieve data format compatibility with 
a range of BioCAD software packages, 
such as Gene Designer. The European 
work on standards involves two aspects: 
the development of standard laboratory 
and other protocols for biopart 
characterisation and assembly (including 
metadata), and the development of a 
comprehensive information standard 
called DICOM-SB. This standard is 
designed to be an extension of the highly 
successful DICOM standard for 
biomedicine. In the jargon, what is being 
developed is a new piece of the standard. 
This will be directly compatible with all 
aspects of the original standard, which is 
widely used by industry.
As globally-applicable applications 
develop, so needs for further 
standardisation are likely to emerge. 
Involvement of the British Standards 
Institution in developing international 
standards (with ISO as appropriate) would 
significantly contribute towards providing 
the consistency required to establish 
working systems and assist UK synthetic 
biology companies to compete globally. 
International involvement in 
education and training
International summer schools are an 
effective method of enabling UK scientists 
to engage with and train in an international 
environment. Effort should be devoted to 
International synthetic biology links to the UK
Funding links:  ESF EuroSYNBIO grants with UK partners
Centres involved in UK – EU FP7 funded projects
Policy links:  Six Academies symposia participants 
*The US is also an observer in ERASynBio 
Funding links:  BBSRC – NSF Enhancing photosynthesis grants 
EPSRC – NSF Synthetic biology sandpit grants
Figure 6: International synthetic biology links to the UK: 
a)  Links between the UK and Europe. Further information about these international links is 
available at: ERASynBio www.erasynbio.net/; EuroSYNBIO www.esf.org/activities/eurocores/
running-programmes/eurosynbio.html; and UK-EU FP7 funded projects http://cordis.europa.
eu/home_en.html
b)  Links between the UK and the rest of the world. Further information on these international links 
can be found at: Six Academies http://blogs.royalsociety.org/in-verba/2011/04/15/;  BBSRC 
- NSF Enhancing Photosynthesis - http://www.bbsrc.ac.uk/news/food-security/2011/110927-f-
increasing-food-and-fuel-production.aspx; EPSRC-NSF sandpit /www.epsrc.ac.uk/
newsevents/news/2009/Pages/syntheticbiologysandpit.aspx
(a) UK – Europe
(b) UK – Rest of the World
Policy links
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establishing international summer schools 
for synthetic biology. These could be 
targeted at specific countries or regions, 
for example within the EU (as is being 
done through ERASynBio) or with the US, 
or left open to all nations, allowing the 
dissemination of UK synthetic biology 
practice more widely. 
Higher degree coordination needs to be 
addressed. What is envisaged is the 
creation of a joint group to share best 
practice in creating curriculums for 
synthetic biology at various levels. 
However, it is not recommended to plan 
and implement any form of joint PhD 
programme involving multiple universities 
– experience has shown that this is 
extremely difficult to achieve because of 
the problem of aligning higher degree 
regulations. A more practical possibility is 
the coordination of, for example, PhD 
programmes where students rotate 
through various laboratories (often in 
different countries), but are registered at a 
single university. One mechanism to 
increase international collaboration would 
be to allow students to undertake research 
rotations or research visits to institutions 
within different countries (similar to the 
British Council ERASMUS scheme). 
As noted previously in theme 1, iGEM has 
been very influential in getting synthetic 
biology recognised internationally. It is a 
highly prestigious student competition. 
Last year, around 130 teams from universities 
all over the world took part and there has 
been good UK representation with UK 
teams winning a number of medals and 
awards at the final. Due to its expanding 
popularity and size, opportunities to 
participate now take place at regional 
levels, not only globally. Participation in the 
competition by UK universities should be 
encouraged to inspire the next generation 
of synthetic biologists. 
Establishing international 
markets and supply-chains
The establishment of international markets 
and supply chains requires a number of 
components to be put in place. Depending 
on the nature of the project and whether or 
not it involves an SME, it will be necessary 
to seek industrial support, funding or 
partnership. If the project is university 
based, then a partnership with a large 
company with international links may be 
most appropriate. This can most 
effectively be done via some form of 
licensing or cooperative research 
agreement. However, large industries are 
well placed to identify appropriate 
research groups to partner with anywhere 
in the world, so ease of working together in 
addition to world-class expertise will be 
important factors in their selection. Smaller 
companies may require more specific 
support to access international markets, 
for example by being assisted in 
developing some form of showcase 
programme that would in turn attract the 
required external investment or partnership. 
An important question is how to develop 
and fund a trained workforce to support a 
solid research base. There is no doubt that 
with knowledge-based industries it is the 
quality of the workforce that is a key factor 
in attracting companies to particular 
locations (the area around Massachusetts 
Institute of Technology is a prime example 
of this phenomenon). The UK is major 
research player; hence it is important to 
put mechanisms in place to attract 
international companies to locate in the UK 
to undertake industrial activity in synthetic 
biology, for example by the creation of 
research campuses built around our 
universities and research institutes.
With sectors like synthetic biology there 
could be a tendency for the technology to 
move abroad once any form of volume 
market has been established (as seen with 
next-generation sequencing), although it 
should be noted that there are also many 
examples of high-tech companies 
retaining a key presence in the UK. By 
considering the opportunities arising whilst 
the sector is still at an early stage, as in 
this roadmap, it may be possible to 
establish a ‘silicon valley’ type environment 
for synthetic biology in the UK that attracts 
inward investment and secures a critical 
mass from which growth may continue to 
flourish locally. 
However, reflecting the increasingly 
interconnected nature of global markets 
and the rapidly growing interest in 
synthetic biology internationally, it is also 
important to consider the nature of this 
core technology in synthetic biology and 
the opportunities that increasing 
globalisation may generate. One approach 
could be to focus on producing new 
generations of the technology and 
providing vehicles for full 
commercialisation, using licensing deals 
to provide revenue streams as specific 
new technologies are rolled out. Another 
would be to take a positive approach 
towards stimulating appropriate end 
market activities, for example, agreeing 
with EU partners to establish a ‘lead 
market initiative’ in synthetic biology, or 
working with the UKTI or FCO to initiate 
specialist trade missions for the sector.  
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Realising the vision
Realising our vision will require an 
integrated approach today guided by  
a long-term view. Success will stem 
from the enterprise and enthusiasm  
of individuals and stakeholder groups 
within the UK community, nurtured 
within a supportive yet clearly 
structured national operating 
environment, itself set within the 
international context. 
The following recommendations address  
a number of critical success factors 
derived from consideration of the material 
summarised in the five themes. These 
need to be taken forward as a whole if the 
sector is to thrive. The purpose of this 
roadmap is to chart options for a way 
forward, but not to pre-empt the outcomes 
of more detailed follow-up studies that 
must necessarily take place, continuing to 
engage experts and the broader 
community as appropriate. 
This roadmap was requested by the UK 
Department for Business Innovation and 
Skills (BIS), and there is a role for 
government in translating the UK’s 
world-leading synthetic biology science 
base into a commercially vibrant and 
viable sector. It should begin with the 
government adopting this roadmap and 
strategic intent. 
A cross-Whitehall strategy group 
appropriately linked to the role of the 
proposed leadership council should be 
established to detail how and where  
the government will support the 
development of this sector with the aim  
of delivering economic growth and 
employment in the UK. 
The important role of 
public investment
Examples from many different 
administrations have highlighted the 
need for public investment to unlock the 
potential of emerging technologies. 
Initial investment by the US Department 
of Defence in DARPANet (Defence 
Advanced Research Projects Agency), 
led to investment in the first network to 
speed up communications between its 
university researchers involved in 
defence research. 
DARPA realised that connecting 
universities and the network had wider 
applications, and moved the project 
into the National Science Foundation. 
NSFNet led to public sector investment 
in servers, high-speed networks  
and initial operations, without which  
the Internet would not have been 
developed as it is.
With suitable infrastructures in place, 
innovative applications can flourish – 
such as the development of  
HyperText Mark-up Language (html)  
by Tim Berners-Lee leading directly  
to the meteoric expansion of the 
world-wide-web.
A synthetic biology roadmap for the UK
UK SYNTHETIC BIOLOGY ROADMAP COORDINATION GROUP | 31
The following section summarises the 
main recommendations arising for 
immediate consideration by BIS. Further 
details and examples may be found under 
the relevant themes.
1. Invest in a network of 
multidisciplinary centres to 
establish an outstanding UK 
synthetic biology resource
 Facilitating communications and 
learning, and networking experts 
across disciplines with customers, 
public and private interest groups are 
common themes running through this 
roadmap. One key element will be to 
provide access to cutting-edge 
resources for both the academic 
community and industry. A single 
multidisciplinary centre already exists 
within the UK, but there is now a need 
to establish a number of additional 
centres to boost the national research 
capacity and diversify our expertise, 
stimulating innovation and facilitating 
the interfaces with industry and other 
key stakeholders. Innovation and 
knowledge centres (IKCs) already 
provide an established mechanism for 
integrating cutting-edge academic 
science with business. Embedding an 
IKC within this overall structure will 
provide the important function of 
academic/business integration. 
1.1 Sufficient resources should be 
deployed within the UK to ensure 
availability of research capacity and a 
full spectrum of essential facilities 
including sequencing and synthesis, 
CAD and robotics commensurate with 
the needs of the innovation community. 
1.2 This multi-centre network should be 
coordinated to provide ‘one-stop’ 
access to critical resources and 
expertise, enhancing developmental 
opportunities for academia and 
industry alike, including leveraging 
capabilities in other relevant institutions 
(such as the European Bioinformatics 
Institute) as appropriate. 
1.3 Centres within this core network should 
also provide an effective training 
environment and venues for 
conferences and other essential 
stakeholder interactions.
1.4 A process should be initiated 
immediately to help define this 
proposed infrastructure, as follows: 
•	establish	the	overall	requirements	
of the multi-centre network in line 
with the roadmap objectives and 
concurrent plans to establish a 
synthetic biology IKC
•	undertake	an	audit	and	prepare	an	
inventory of resources currently 
available
•	determine	essential	resource	
requirements, based on the 
inventory and what is needed to 
meet the roadmap objectives
•	define	an	appropriate	configuration	
(and optimal number) of centres 
that will deliver the whole concept
•	estimate	overall	costs	and	timescales
•	 report	to	the	proposed	leadership	
council in autumn 2012.
2. Build a skilled, energised and 
well-funded UK-wide synthetic 
biology community
 Complementary to recommendation 1 
above, which focuses on boosting our 
foundational and applied research 
base, attention should be given to 
developing a skilled, energised, 
responsible and well-funded 
community. This will involve stimulating 
cross-disciplinary interactions and 
sharing best practice, encouraging 
innovative research proposals and 
facilitating the development of valuable 
applications. Together with the 
provision of further guidance on 
responsible research and innovation 
and other training initiatives, an 
increasingly secure and confident 
‘can-do’ culture should be established. 
2.1 Community building. Develop a 
synthetic biology special interest group 
(SIG) to facilitate interactions across the 
community by fostering coordinated 
efforts, showcasing events and 
engendering a greater awareness of 
funding mechanisms to pursue 
opportunities.
2.2 Embedding responsible innovation. 
Public sector investment in synthetic 
biology should take into account social, 
ethical and regulatory issues and 
increase awareness of responsible 
innovation via training programmes. 
This will include on-going stakeholder 
engagement and dialogue with wider 
social groups. 
2.3 Training. The next generation synthetic 
biology community needs to comprise 
researchers with (a) depth within core 
disciplines and the ability to work in 
cross-disciplinary collaboration; and (b) 
high-level, broad interdisciplinary 
synthetic biology expertise. Training 
should also integrate broader societal 
and business contexts and 
understanding. Doctoral training should 
be included as an important element 
within the multidisciplinary centres. 
Further training mechanisms include:
•	 identified	students	to	have	
cross-disciplinary supervision and 
experience of working in industry 
through professional internships. 
Students should be educated in 
societal and ethical issues and 
provided with opportunities for 
technical and management training
•	summer	schools	and	short	courses:	
targeted to meet the common and 
different needs of industrial and 
academic researchers. Courses 
could include introduction to core 
principles, training in platform 
technologies, and business 
development. 
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3. Invest to accelerate technology 
responsibly to market 
 An essential activity in commercialising 
disruptive emerging technologies is to 
undertake an iterative process of 
matching technology with potential 
market opportunities, and 
demonstrating that the potential 
benefits can be achieved in order to 
attract the investment required. This 
can be hard to justify for companies 
where the precise value proposition or 
business model is still unclear. The UK 
should invest to help innovators to 
create new products, processes or 
services using synthetic biology in a 
responsible way. Because synthetic 
biology is at an early stage it is possible 
that it may find application in a myriad 
of ways as yet unconsidered. An 
open-ended innovative approach to 
early-stage research must also be 
preserved and stimulated and not 
constrained to market situations as 
currently understood.
3.1 Help companies evaluate the potential 
of synthetic biology in their markets, 
linking outstanding science to real-
world commercial opportunities, for 
example by: 
•	 facilitating	access	to	expertise	and	
facilities 
•	setting	strategic	targets	that	could	
stimulate market demand.
3.2 Technology Strategy Board, with 
research council partners and other 
investors, should invest in:
•	small-scale	feasibility	studies	to	
test out ideas in a wide range of 
application areas
•	 larger-scale	R&D	projects	to	
demonstrate the technology for 
promising applications.
3.3 Help companies embed best practice 
use of synthetic biology technology in 
their organisations through targeted 
programme of Knowledge Transfer 
Partnership (KTPs).
3.4 Ensure provision of an impartial 
resource to help innovators in the area 
to evaluate the ethical, social, 
regulatory and business issues raised 
by their proposed innovations, such 
that the maximum benefits of the 
technology can be achieved.
3.5 Promote the use of responsible 
innovation across the sector by:
•	 increasing	levels	of	interaction	
between the synthetic biology 
research community and risk 
regulatory bodies, ensuring that the 
legislative framework continues to 
adequately encompasses novel 
entities as they arise
•	 translating	the	principles	of	
continuing responsible research 
and innovation into the funding 
mechanisms and related activities 
recommended in this roadmap. 
4. Assume a leading international role 
 International collaboration is an 
essential factor underpinning progress 
in synthetic biology, reflecting the 
increasingly knowledge-based and 
interconnected nature of 21st-century 
society. Clear economic benefits derive 
from increasing scientific activity 
between countries, and this expectation 
lies behind a range of initiatives, 
including joint research programmes in 
synthetic biology between funders in 
the US and Europe and China. 
Whereas the UK is considered to lead 
synthetic biology in Europe, our total 
research funding is significantly lower 
than in the US. On the other hand, 
overall research effort across Europe 
including the UK is comparable to the 
US, placing the UK in a prime position 
to continue its leading international role, 
for example in helping to establish 
international standards, both technical 
and regulatory. A number of 
mechanisms should be invoked to 
promote this position. 
4.1 The British Government should play a 
leading, proactive role in promoting 
synthetic biology internationally, 
particularly in the US, China and within 
the EU (for example through the EU 
Bio-economy Initiative and Horizon 2020). 
4.2 The UK should work with other countries 
on the development of IP frameworks 
that establish a more constructive 
balance between the benefits of open 
information exchange at the foundational 
level and the opportunity to protect 
valid proprietary developments.
4.3 The UK should work with other 
countries on the development of 
regulations and a governance model 
for the field that is robust and 
proportionate and adopted 
internationally.
4.4 The UK should establish mechanisms 
to promote the UK as a centre for 
international conferences in the field and 
help coordinate international activity in 
advanced training in synthetic biology.
5.  Establish a leadership council
 The range of potential synthetic biology 
applications and the corresponding 
number of bodies involved in different 
aspects of synthetic biology mean 
there is a need for one body to be a 
visible point of coordination. We 
envisage this to be a leadership 
council. We propose that the 
leadership council owns and oversees 
the continual development and delivery 
of the vision and roadmap. 
5.1 The leadership council should act as a 
focal point for the development of the 
synthetic biology sector in the UK, 
bringing together key interested 
stakeholders representing a wide 
diversity of interests, including: 
industrialists; leading academics; 
regulators; social scientists; the 
research councils; Technology Strategy 
Board; learned societies; NGOs; other 
stakeholders; and relevant government 
departments. 
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5.2  It should provide an exemplar of 
openness and transparency with 
two-way stakeholder engagement as a 
core principle. 
5.3 The group should meet three times a 
year, with at least one meeting held in 
public. The activity of the council 
should be supported by ongoing 
dialogue via social media. 
5.4 There is a need for a leadership council 
to be a visible point of coordination, 
however there are many bodies in this 
field, each with a different remit. We 
would encourage and expect members 
of the leadership council to work with, 
and where appropriate sit on these 
other bodies. 
5.5. The work of the leadership council 
should be supported by sub-groups, 
appointed by the council, which will 
deliver discrete pieces of work, for 
example engagement, regulation, or 
international collaboration. We would 
encourage membership of these 
groups to be broader than that of the 
leadership council, and to incorporate 
a much wider cohort of stakeholders. 
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Footnote
This roadmap draws upon materials and inputs generated by participants in the two workshops and also reflects ideas drawn from a 
wide range of other relevant sources. It seeks to reflect a representative view drawn from within the UK community, but does not purport 
to represent the totality of views that may exist within the UK – further engagement as an ongoing process is a specific 
recommendation. Nor does it necessarily represent the views of those bodies with whom individual coordination group members are 
affiliated. Information on markets and trends has been drawn from publicly-available data to illustrate possible futures for synthetic 
biology, but should not be interpreted as a recommendation and no liability may be accepted by the contributors to this study in regard 
to any investment decisions taken on the basis of this material. 
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